

## INDEX TO VOLUME 21

### AUTHOR INDEX

- Abdel-Gawad, A.H.E., 479  
 Abdel-Hay, M.M., 479  
 Allonen, H., 321  
 Amatayakul, K., 283  
 Andrade, A.T.L., 343  
 Angelo, S., 585  
 Aubert, J.M., 577  
 Babu, S., 53  
 Back, D.J., 135, 145  
 Baggett, B., 115  
 Bain, J., 365  
 Baumann, R., 191  
 Benoit, H.J., 41  
 Beuving, D.C., 353  
 Bolt, H.M., 145  
 Boots, L.R., 659  
 Boria, M.D., 577  
 Borth, R., 41  
 Brekenridge, A.M., 135, 145  
 Bruzzzone, M.E., 585  
 Bygdeman, M., 571  
 Carenza, L., 311  
 Casper, R.F., 471  
 Chang, M.C., 77, 461  
 Channiniyom, K., 299  
 Crawford, F.E., 135, 145  
 Custo, G.M., 311  
 Damgaard-Pedersen, F., 381  
 de la Pena, A., 1, 17  
 Demers, L.M., 551  
 de Souza, J.P., 343  
 Dhawan, B.N., 29  
 Diczfalusy, E., 87, 415  
 Dozier, T.S., 1, 17  
 Dusitsin, N., 299  
 El-Sawy, M., 479  
 Engineer, A.D., 29  
 Etchell, D.M., 335  
 Findley, W.E., 199  
 Foegh, M., 381, 631  
 Fortney, J.A., 235  
 Frankman, O., 571  
 Freund, H., 641  
 Gentzschlein, E., 595  
 Gibor, Y., 491  
 Ghosh, T., 183  
 Gobeaux-Castadot, M.-J., 577  
 Goldzieher, J.W., 1, 17  
 Goncharov, N.P., 537  
 Goresky, D.M., 335  
 Gormsen, J., 381  
 Green, K., 571  
 Greenspan, A.R., 563  
 Guirgis, F.K., 479  
 Gupta, G.N., 165  
 Gupta, K., 617  
 Gutknecht, G.D., 353  
 Gu, Z., 461  
 Hahn, D.W., 529, 551  
 Hall, J.M., 135  
 Hammerstein, J., 393  
 Hasan, M., 433  
 Hatcher, R.A., 563  
 Hazari, K., 617  
 Hesse, G., 641  
 Honore, L.H., 47  
 Islam, F., 433  
 Jacobs, B.R., 199  
 Jahan, F.A., 207  
 Joshi, J.V., 617  
 Joshi, U.M., 165, 617  
 Kamboj, V.P., 29  
 Khait, Z., 365  
 Kahn, A.R., 207  
 Khanna, N.M., 29  
 Kholkute, S.D., 165  
 Knecht, M., 425  
 Knudsen, J.B., 381  
 Koh, S., 505  
 Kuhl, H., 191  
 Kurischko, A., 61, 537  
 Kutty, D., 29  
 Lahteenmäki, P., 155, 225  
 Landgren, B.-M., 87, 415  
 Lau, I.F., 77  
 Lauersen, N.H., 273  
 Leepipatpaiboon, S., 299  
 Lumkin, M., 595

## CONTRACEPTION

- Luukkainen, T., 155, 225, 321  
 Macaulay, L.K., 343  
 MacIver, M., 135  
 Maitra, A., 165  
 McConnell, R.F., 529  
 McGuire, J.L., 529, 551  
 Mehta, S., 217  
 Michaels, T., 175  
 Mishell, D.R., Jr., 595  
 Mitchell, C., 491  
 Moberg, P., 571  
 Moltz, L., 393  
 Moore, M., 563  
 Munshi, S.R., 165  
 Nandi, R.C., 29  
 Nash, H.A., 115  
 Nayyar, S.K., 183  
 Nichol, K., 631  
 Nielsen, N.-C., 321  
 Nilsson, C.G., 155, 225  
 Nygren, K.-G., 321  
 Oettel, M., 61, 537, 641  
 Oriowo, M.A., 415  
 Orme, M.L.E., 135, 145  
 Ory, H.W., 563  
 Osman, S.M., 433  
 Pala, A., 311  
 Petersen, I.B., 631  
 Post, K., 393  
 Prema, K., 53  
 Pyörälä, T., 321  
 Rachlis, V., 365  
 Ramalakshmi, B.A., 53  
 Rao, A.P., 617  
 Ratnam, S.S., 505  
 Rizvi, R., 433  
 Robert, E., 365  
 Römmler, A., 393  
 Rosenberg, M.J., 563  
 Rowe, P.H., 135, 145, 343  
 Sairam, M.R., 651  
 Saleh, F.M., 479  
 Sandberg, C.-G., 571  
 Sandow, J., 191  
 Sankolli, G.M., 617  
 Sarin, J.P.S., 29  
 Saxena, B.N., 217, 617  
 Schindler, A.E., 145  
 Schou, G., 381, 631  
 Schubert, K., 537  
 Schwartz, U., 393  
 Setty, B.S., 29  
 Shaw, S.T., Jr., 343  
 Sheehan, K., 471  
 Sheth, U.K., 617  
 Singh, L., 29  
 Singh, S., 29  
 Singkamani, R., 283  
 Sivassomboon, B., 283  
 Smith, E., 135  
 Smith, R.P., 335  
 Southern, E.M., 353  
 Spilman, C.H., 353  
 Stanczyk, F., 595  
 Stenström, B., 415  
 Strecke, J., 537  
 Subhas, T., 175  
 Swenson, I., 207  
 Taubert, H.-D., 191  
 Tejuja, S., 165  
 Toddywalla, V.S., 217  
 Tsakok, F.H.M., 505  
 Vaivanijkul, B., 299  
 Vengadasalam, D., 235  
 Virkar, K.D., 217  
 Virutamasen, P., 299  
 Wang, C., 245  
 Watts, M.J., 135  
 Werawatgoompa, S., 299  
 WHO 121, 445  
 Williams, S.A., 659  
 Wilson, K.H., 273  
 Woolever, C.A., 41  
 Yen, S.S., 471  
 Yeung, K.K., 245  
 Zipper, J., 585

## INDEX TO VOLUME 21

### SUBJECT INDEX

- Abnormal spermatozoa,
  - effect of oral cyproterone acetate, 393
  - effect of oral levo-norgestrel + monthly testosterone enanthate, 631
  - effect of oral levo-norgestrel + testosterone, 381
- Abortifacient effects, root of *Trichosarthis kirilowii* (mouse, rabbit, 77
- Acceptability of drugs, male fertility regulation, 121
- Actinomyces in endometrium, use of IUD, 577
- Adverse effects, oral medroxyprogesterone acetate + methyltestosterone (male), 365
- Alpha-feto protein levels, effect of oral contraceptive use, 53
- Antagonistic activity, deglycosylated ovine LH (rat), 651
- Anti-deciduogenic activity, STS 557 (rat), 537
- Antifertility activity of hCG, species differences (mouse, rat, hamster), 551
- Antigonadotropic activity, *Lithospermum ruderales*, 199
- Antiprogestational properties, STS 557 (rabbit), 61
- Anti-tubercular drugs, interaction of ethinyl estradiol + norethisterone acetate, 617
- Aspartate aminotransferase activity in kidney and uterus,
  - effect of ethinylestradiol (rat), 659
  - effect of ethinylestradiol + norgestrel (rat), 659
  - effect of norgestrel (rat), 659
- Association of depo-medroxyprogesterone acetate and breast cancer, 563
- Bioabsorbable implant, norethisterone release (monkey), 165
- Biodegradable implant,
  - norethisterone, 217
  - d-norgestrel, 217
- 3,5-Bis(dimethylamino)-1,2,4-dithiazolium chloride (ORF 5513),
  - effect on ovulation (rat), 529
  - effect on pregnancy (rat), 529
- Bleeding and ovulation, effect of levonorgestrel-releasing IUD, 155
- Bleeding episodes, subcutaneous rods containing levonorgestrel, 595
- Bleeding pattern,
  - levonorgestrel-releasing IUD, 225
  - norethisterone minipill, 87
  - subcutaneous rods containing levonorgestrel, 595
- Bleeding/pain, effect of progesterone-releasing IUD, 491
- Blood coagulation tests, effect of oral contraceptives containing 50 µg estrogen, 505
- Brain, regional lipid levels after ethinylestradiol + norgestrel (rabbit), 433
- Breast cancer,
  - association of depo-medroxyprogesterone acetate, 563
  - relative risk of oral contraceptive use, 563
- Breast milk, effect of different drug delivery systems on levels of contraceptive steroids, 217
- Carbohydrate metabolism, effect of medroxyprogesterone acetate, 283

## CONTRACEPTION

- Cardiovascular disease and serum lipoproteins, effects of contraceptive steroids, 115
- Cervical dilatation prior to vacuum aspiration, vaginal 15-methyl-PGF<sub>2α</sub> methyl ester suppository, 571
- Cervical dilator, use of Isaptent, 29
- Choriocarcinoma implant, effect of hCGβ-tt immunization on ovarian morphology (hamster), 425
- Clinical and endocrinologic study, subcutaneous rods containing levonorgestrel, 595
- Clinical examination, oral cyproterone acetate (male), 245
- Coagulation factors, effect of oral levo-norgestrel + testosterone (male), 381
- Combination oral male contraceptive,
  - levo-norgestrel + testosterone, 381
  - medroxyprogesterone acetate + methyltestosterone, 365
- Comparative study,
  - ethinyl estradiol + norethisterone acetate vs. estradiol + estriol + norethisterone acetate, 445
  - norethindrone enanthate vs. depo-medroxyprogesterone acetate, 207
  - Nova T and Cooper T 200, 321
- Complaints reported, ethinyl estradiol + norethisterone acetate vs. estradiol + estriol + norethisterone acetate, 445
- Contraceptive steroid release through different drug delivery systems into serum and breast milk, 217
- Contraceptive steroids, effect on serum lipoproteins and cardiovascular disease, 115
- Contraceptational properties, STS 557 (rabbit), 61
- Copper 7, Actinomyces in endometrium, 577
- Copper IUD, five years experience in nulliparous women, 335
- Copper T, quantitative menstrual and intermenstrual blood loss, 343
- Copper T 200 and Nova T, comparative study, 321
- Copper-releasing IUD, Nova T and Copper T 200, 321
- 17α-Cyanomethyl-17β-hydroxy-estra-4,9(10)-diene-3-one (STS 557),
  - anti-deciduogenic activities (rat), 537
  - antiprogestational properties (rabbit), 61
  - contragestational properties (rabbit), 61
  - effect on fertility (male rabbit), 641
  - effect on maintenance of early pregnancy (rat), 537
  - effect on semen characteristics (rabbit), 641
  - effect on sexual behavior (male rabbit), 641
  - interceptive action (mouse, rat, guinea pig, baboon), 537
  - orally active progestin (rabbit), 61
- Cyproterone acetate,
  - acceptability for male fertility regulation, 121
  - effect on hormone secretion (male), 393
  - effect on organ weights (rat), 183
  - effect on spermatogenesis, 393
  - hormonal measurements (male), 245
  - oral male contraceptive, 245, 393
  - seminal fluid analyses, 245

- Cyproterone acetate and seminal vesicles, regulation of male fertility (rat), 183
- Dalkon Shield, Actinomyces in endometrium, 577
- Deglycosylated ovine LH, effect on LH-induced ovulation (rat), 651
- Depo-medroxyprogesterone acetate, association of breast cancer, 563
- Depo-medroxyprogesterone acetate vs. norethindrone enanthate, randomized, single blind comparative trial, 207
- Depot-medroxyprogesterone acetate,
  - effect on liver function tests, 479
  - effect on serum phospholipid fractionation, 479
- Depot-medroxyprogesterone acetate + testosterone cypionate, acceptability for male fertility regulation, 121
- Detection of ovulation, electrochemical vaginal-oral potentials, 585
- Detection of pre-ovulatory period, use of vaginal probe, 41
- Different populations,
  - plasma levels and pharmacokinetics of ethynylestradiol, 1
  - plasma levels and pharmacokinetics of mestranol, 17
- Dihydrotestosterone level,
  - effect of oral cyproterone acetate (male), 393
  - effect of oral medroxyprogesterone acetate + methyltestosterone (male), 365
- Dilatation of cervix, use of Isapient, 29
- Dilatation of cervix prior to vacuum aspiration, vaginal 15-methyl-PGF<sub>2α</sub> methyl ester suppository, 571
- Discontinuation,
  - effect of oral levo-norgestrel + monthly testosterone enanthate (male), 631
  - norethindrone enanthate vs. depo-medroxyprogesterone acetate, 207
- Discontinuation rates, ethinyl estradiol + norethisterone acetate vs. estradiol + estriol + norethisterone acetate, 445
- Disposable menstrual regulation kits, durability in non-throw-away economy, 235
- Drug delivery systems, effect on levels of contraceptive steroids in serum and breast milk, 217
- Durability of disposable menstrual regulation kits, non-throw-away economy, 235
- Early pregnancy interruption, two 15-ME-PGF<sub>2α</sub> suppositories, 273
- Electrochemical vaginal-oral potentials, changes during menstrual cycle, 585
- Endocrinologic and clinical study, subcutaneous rods containing levonorgestrel, 595
- Endometrial biopsies, subcutaneous rods containing levonorgestrel, 595
- Estradiol + estriol + norethisterone acetate vs. ethinyl estradiol + norethisterone acetate, randomized, double-blind study, 445
- Estradiol and estrone levels, intramuscular administration of various estradiol esters, 415
- Estradiol benzoate,
  - pharmacokinetic properties, 415
  - plasma levels of estradiol and estrone, 415
- Estradiol cypionate,
  - pharmacokinetic properties, 415
  - plasma levels of estradiol and estrone, 415

## CONTRACEPTION

- Estradiol esters, pharmacokinetic properties, 415
- Estradiol level,
  - effect of daily administration of HOE 766 (LH-RH analog), 191
  - effect of injectable norethisterone oenanthate, 299
  - effect of levonorgestrel-releasing IUD, 155, 225
  - effect of LRF-agonist (D-Trp<sup>6</sup>, Pro<sup>9</sup> NEt)-LRF and hCG, 471
  - effect of oral cyproterone acetate (male), 245
  - norethisterone minipill, 87
  - subcutaneous rods containing levonorgestrel, 595
- Estradiol valerate,
  - pharmacokinetic properties, 415
  - plasma levels of estradiol and estrone, 415
- Estrogen level, effect of hCG during pregnancy (rat), 551
- Estrogen-containing oral contraceptives, effect on blood coagulation, 505
- Ethinylestradiol, effect on uterine and kidney aspartate aminotransferase activity (rat), 659
- Ethinyl estradiol + levonorgestrel treatment, pharmacokinetic properties of estradiol esters, 415
- Ethinyl estradiol + norethisterone, levels in serum and breast milk, 217
- Ethinyl estradiol + norethisterone acetate,
  - effect of anti-tubercular drugs, 617
  - effect of isonicotinic acid hydrazide treatment, 617
  - effect of paraaminosalicylic acid treatment, 617
  - effect of Rifampicin treatment, 617
- Ethinyl estradiol + norethisterone acetate vs. estradiol + estriol + norethisterone acetate, randomized, double-blind study, 445
- Ethinylestradiol + norgestrel,
  - effect on regional lipid levels of brain (rabbit), 433
  - effect on uterine and kidney aspartate aminotransferase activity (rat), 659
  - levels in serum and breast milk, 217
- Ethinyl estradiol levels, effect of anti-tubercular drugs, 617
- Ethinylestradiol,
  - effect of Rifampicin on pharmacokinetics, 135
  - pharmacokinetics, 1, 145
  - plasma levels, 1
- Ethinylestradiol + injectable norethisterone oenanthate, effect on ovarian hormones, 299
- Ethinylestradiol + norethindrone acetate, effect of Rifampicin on pharmacokinetics, 135
- Ethinyl estradiol + norgestrel, effect on plasma alpha-feto protein levels, 53
- Ethinylestradiol + norgestrel + injectable norethisterone oenanthate, effect on ovarian hormones, 299
- Ethinylestradiol glucuronide level, large oral dose ethinylestradiol, 145
- Ethinylestradiol levels, pharmacokinetics of mestranol, 17
- Ethinylestradiol sulphate level, large oral dose ethinylestradiol, 145
- Expulsion, effect of progesterone-releasing IUD, 491
- Fertility, effect of STS 557 (male rabbit), 641

- Fibrinolytic activity and capacity,
  - effect of oral levo-norgestrel + monthly testosterone enanthate (male), 631
  - effect of oral levo-norgestrel + testosterone (male), 381
- Fibrinolytic tests, effect of oral contraceptives containing 50 µg estrogen, 505
- Five years experience, copper IUDs in nulliparous women, 335
- Follicle stimulating hormone (FSH),
  - Fructose content in semen, effect of STS 557 (rabbit), 641
  - FSH (follicle stimulating hormone)
- FSH level,
  - effect of daily administration of HOE 766 (LH-RH analog), 191
  - effect of levonorgestrel-releasing IUD, 155, 225
  - effect of oral cyproterone acetate (male), 245, 393
  - effect of oral levo-norgestrel + monthly testosterone enanthate (male), 631
  - effect of oral levo-norgestrel + testosterone (male), 381
  - effect of oral medroxyprogesterone acetate + methyltestosterone (male), 365
  - effect of progesterone-releasing IUD, 311
- Glucose tolerance test, effect of medroxyprogesterone acetate, 283
- Gossypol acetic acid, effect on male fertility (rat, hamster, rabbit), 461
- hCG (human chorionic gonadotropin)
  - hCG level,
    - effect of 15-ME-PGF<sub>2α</sub> suppository, 273
    - effect of progesterone-releasing IUD, 311
    - vaginal suppository containing 15(S)-15-methyl-PGF<sub>2α</sub> methyl ester, 353
  - hCGβ-tt(beta subunit of human chorionic gonadotropin coupled to tetanus toxoid),
  - hCGβ-tt immunization, effect on ovarian morphology when implanted with human choriocarcinoma (hamster), 425
- Heating of scrotum prior to vasectomy,
  - influence on sperm granuloma formation, 175
  - influence on testicular activity, 175
- Heteroploidy-correlated structural abnormalities in spontaneous abortuses,
  - effect of IUD, 47
- HOE 766 (D-Ser(TBU)<sup>6</sup>-LH-RH-(1-9)-nonapeptide-ethylamide, LH-RH analog)
- Home use of vaginal probe, detection of pre-ovulatory period, 41
- Hormonal antagonist, deglycosylated ovine LH (rat), 651
- Hormonal effects, norethisterone minipill, 87
- Hormonal measurements, oral cyproterone acetate (male), 245
- Hormone levels, effect of oral levo-norgestrel + testosterone (male), 381
- Hormone profiles, levonorgestrel-releasing IUD, 225
- Hormone secretion, effect of oral cyproterone acetate (male), 393
- Human chorionic gonadotropin (hCG),
  - effect on luteolytic action of LRF-agonist (D-Trp<sup>6</sup>,Pro<sup>9</sup>NET)-LRF, 471
  - mechanism of antifertility activity (rat), 551
- 17α-Hydroxyprogesterone caproate + testosterone oenanthate, acceptability for male fertility regulation, 121
- Immunization with hCGβ-tt, effect on ovarian morphology when implanted with human choriocarcinoma (hamster), 425
- Implant, levonorgestrel rods, 595
- Implantation sites of females, effect of male treated with Gossypol acetic acid (rat, hamster), 461

## CONTRACEPTION

- Implantation with human choriocarcinoma, effect of hCG $\beta$ -tt immunization on ovarian morphology (hamster), 425
- Induction of menses, vaginal 15(S)-15-methyl-PGF $_{2\alpha}$  methyl ester suppository, 353
- Inhibition of LH-induced ovulation, effect of deglycosylated ovine LH (rat), 651
- Inhibition of ovulation, daily administration of HOE 766 (LH-RH analog), 191
- Injectable contraceptive,
  - depo-medroxyprogesterone acetate, 207, 563
  - depot-medroxyprogesterone acetate, 479
  - medroxyprogesterone acetate, 283
  - norethindrone enanthate, 207
  - norethisterone oenanthate, 299, 479
- Injectable norethisterone oenanthate, effect on ovarian hormones, 299
- Injectable norethisterone oenanthate + ethynylestradiol, effect on ovarian hormones, 299
- Injectable norethisterone oenanthate + ethynylestradiol + norgestrel, effect on ovarian hormones, 299
- Insertion problems, copper IUDs in nulliparous women, 325
- Interaction of low-dose combination oral contraceptive with anti-tubercular drugs, 617
- Interceptive action, STS 557 (mouse, rat, guinea pig, baboon), 537
- Intermenstrual blood loss, Lippes loop C and copper T, 343
- Intramuscular administration of estradiol esters, pharmacokinetic properties, 415
- Intrauterine contraceptive device (IUD),
  - copper, 335
  - copper T, 343
  - copper T 200, 321
  - effect on morphologic abnormalities in spontaneous abortions, 47
  - levonorgestrel-releasing, 155, 225
  - Lippes loop C, 343
  - Nova T, 321
  - progesterone-releasing, 311, 491
- Isapent, cervical dilator made from *Plantago ovata* seed husk powder, 29
- Isonicotinic acid hydrazide, interaction of ethinyl estradiol + norethisterone acetate, 617
- IUD (intrauterine contraceptive device)
- IUD users, Actinomyces in endometrium, 577
- Kidney aspartate aminotransferase activity,
  - effect of ethinylestradiol (rat), 659
  - effect of ethinylestradiol + norgestrel (rat), 659
  - effect of norgestrel (rat), 659
- Large oral dose (3 mg) ethinylestradiol, pharmacokinetics, 145
- Levo-norgestrel + testosterone,
  - effect on coagulation factors (male), 381
  - effect on hormone levels (male), 381
  - effect on lipoproteins (male), 381
  - effect on spermatogenesis, 381
  - oral male contraceptive, 381



- Levo-norgestrel + testosterone enanthate, clinical evaluation of long-term treatment (male), 631
- Levonorgestrel level,
  - effect of levonorgestrel-releasing IUD, 155, 225
  - subcutaneous rods containing levonorgestrel, 595
- Levonorgestrel-containing subcutaneous rods, clinical and endocrinologic study, 595
- Levonorgestrel-releasing IUD,
  - pattern of bleeding, 225
  - patterns of ovulation and bleeding, 155
  - plasma concentrations and hormone profiles, 225
- LH (luteinizing hormone)
- LH level,
  - effect of daily administration of HOE 766 (LH-RH analog), 191
  - effect of levonorgestrel-releasing IUD, 155, 225
  - effect of oral cyproterone acetate (male), 245, 393
  - effect of oral levo-norgestrel + monthly testosterone enanthate (male), 631
  - effect of oral levo-norgestrel + testosterone (male), 381
  - effect of oral medroxyprogesterone acetate + methyltestosterone (male), 365
  - effect of progesterone-releasing IUD, 311
- LH-induced ovulation, effect of deglycosylated ovine LH (rat), 651
- LH-RH (luteinizing hormone releasing hormone),
  - LH-RH analog (D-Ser(TBU)<sup>6</sup>-LH-RH-(1-9)-nonapeptide-ethylamide = HOE 766), ovulation inhibition by daily administration, 191
- LH-RH double stimulation, effect of oral cyproterone acetate (male), 393
- Lipids, effect of medroxyprogesterone acetate, 283
- Lipids in discrete brain areas, effect of ethinylestradiol + norgestrel (rabbit), 433
- Lipoproteins, effect of oral levo-norgestrel + testosterone (male), 381
- Lipoproteins and cardiovascular disease, effect of contraceptive steroids, 115
- Lippes loop, Actinomyces in endometrium, 577
- Lippes loop C, quantitative menstrual and intermenstrual blood loss, 343
- Lithospermum ruderales,
  - antigonadotropic activity, 199
  - effect on steroid receptors, 199
- Liver function tests,
  - effect of medroxyprogesterone acetate, 283, 479
  - effect of norethisterone oenanthate, 479
- Long-term treatment with levo-norgestrel + testosterone enanthate (male), 631
- LRF (luteinizing hormone releasing factor)
- LRF-agonist (D-Trp<sup>6</sup>,Pro<sup>9</sup>NET)-LRF,
  - effect of hCG on luteolytic action, 471
  - effect on serum levels of  $\beta$ hCG, estradiol and progesterone following three doses, 471
  - effect on serum levels of  $\beta$ -hCG, estradiol and progesterone in early pregnancy, 471
- Luteinizing hormone (LH)
- Luteinizing hormone releasing factor (LRF)

## CONTRACEPTION

- Luteinizing hormone releasing hormone (LH-RH)
- Luteolytic action of LRF-agonist (D-Trp<sup>6</sup>,Pro<sup>9</sup>NET)-LRF, effect of hCG, 471
- Maintenance of early pregnancy, STS 557 (rat), 537
- Maintenance of pregnancy during hCG treatment, effect of progesterone, anti-hCG and ovariectomy (rat), 551
- Male contraceptive,
  - oral cyproterone acetate, 245, 393
  - oral levo-norgestrel + monthly testosterone enanthate, 631
  - oral levo-norgesterl + testosterone, 381
  - oral medroxyprogesterone acetate + methyltestosterone, 365
- Male fertility, effect of Gossypol acetic acid (rat, hamster, rabbit), 461
- Male fertility regulation,
  - acceptability of drugs, 121
  - cyproterone acetate and seminal vesicles (rat), 183
  - measurement of sexual functioning, 121
- Male user's evaluations of hormonal methods, 121
- Mechanism of antifertility activity, hCG (rat), 551
- Medroxyprogesterone acetate, effect on serum lipids, protein, glucose tolerance and liver function, 283
- Medroxyprogesterone acetate + methyltestosterone,
  - acceptability for male fertility regulation, 121
  - oral male contraceptive, 365
- Medroxyprogesterone acetate + testosterone oenanthate, acceptability for male fertility regulation, 121
- Menses induction, vaginal 15(S)-15-methyl-PGF<sub>2α</sub> methyl ester suppository, 353
- Menstrual and intermenstrual blood loss, Lippes loop C and copper T, 343
- Menstrual complaints, ethinyl estradiol + norethisterone acetate vs. estradiol + estriol + norethisterone acetate, 445
- Menstrual cycle, measurement of electrochemical vaginal-oral potentials, 585
- Menstrual irregularities, ethinyl estradiol + norethisterone acetate vs. estradiol + estriol + norethisterone acetate, 445
- Menstrual patterns, norethindrone enanthate vs. depo-medroxyprogesterone acetate, 207
- Menstrual regulation kits in non-throw-away economy, 235
- 15-ME-PGF<sub>2α</sub> (15(S)-15-methyl-prostaglandin F<sub>2α</sub>)
- 15-ME-PGF<sub>2α</sub> level, 15-ME-PGF<sub>2α</sub> suppositories for early pregnancy interruption, 273
- Mestranol,
  - pharmacokinetics, 17
  - plasma levels, 17
- 15-Methyl-PGF<sub>2α</sub> methyl ester, vaginal suppository for dilatation of cervix prior to vacuum aspiration, 571
- 15-Methyl-PGF<sub>2α</sub> plasma concentration, vaginal suppository containing 15(S)-15-methyl-PGF<sub>2α</sub> methyl ester, 353
- Methyltestosterone + medroxyprogesterone acetate,
  - acceptability for male fertility regulation, 121
  - oral male contraceptive, 365

- Minipill, norethisterone, 87
- Morphologic abnormalities in spontaneous abortions, effect of IUD, 47
- Non-Caucasian women, effects of oral contraceptives containing 50 µg estrogen on blood coagulation, 505
- Non-throw-away economy, use of disposable menstrual regulation kits, 235
- Norethindrone enanthate vs. depo-medroxyprogesterone acetate, randomized, single blind comparative trial, 207
- Norethindrone level, effect of injectable norethisterone oenanthate, 299
- Norethisterone, levels in serum and breast milk, 217
- Norethisterone + cholesterol,
  - bioabsorbable implant (monkey), 165
  - biodegradable implant, 217
- Norethisterone level,
  - effect of anti-tubercular drugs, 617
  - norethisterone minipill, 87
  - norethisterone release from bioabsorbable implant (monkey), 165
- Norethisterone minipill, hormonal effects, 87
- Norethisterone oenanthate,
  - effect on liver function tests, 479
  - effect on ovarian hormones, 299
  - effect on serum phospholipid fractionation, 479
- Norethisterone oenanthate in Thai women, 299
- Norethisterone oenanthate level, effect of injectable norethisterone oenanthate, 299
- Norethisterone release, bioabsorbable implant (monkey), 165
- Norgestrel, effect on uterine and kidney aspartate aminotransferase activity (rat), 659
- d-Norgestrel, levels in serum and breast milk, 217
- d-Norgestrel + cholesterol, biodegradable implant, 217
- Nova T and copper T 200, comparative study, 321
- Nulliparous women, five years experience with copper IUDs, 335
- Oral contraceptive,
  - effect on plasma alpha-feto protein levels, 53
  - estradiol + estrinol + norethisterone acetate, 445
  - ethinyl estradiol + norethisterone, 217
  - ethinyl + estradiol + norethisterone acetate, 445, 617
  - ethinyl estradiol + d-norgestrel, 217
  - ethynylestradiol + norethindrone acetate, 135
  - ethynyl estradiol + norgestrel, 53
  - norethisterone, 87, 217
  - d-norgestrel, 217
- Oral contraceptive use, relative risk of breast cancer, 563
- Oral contraceptive users, measurement of electrochemical vaginal-oral potentials, 585
- Oral contraceptives, effect on serum lipoproteins and cardiovascular disease, 115
- Oral contraceptives containing 50 µg estrogen,
  - effect on blood coagulation, 505
  - effect on fibrinolytic tests, 505
  - effect on platelet function, 505

## CONTRACEPTION

- Oral male contraceptive,
  - cyproterone acetate, 245, 393
  - levo-norgestrel + testosterone, 381
  - medroxyprogesterone acetate + methyltestosterone, 365
- ORF 5513 (3,5-bis(dimethylamino)-1,2,4-dithiazolium chloride)
- Ovarian hormones, effect of injectable norethisterone oenanthate, 299
- Ovarian morphology, effect of hCG $\beta$ -tt immunization and implantation with human choriocarcinoma (hamster), 425
- Ovulation, effect of ORF 5513 (rat), 529
- Ovulation and bleeding, effect of levonorgestrel-releasing IUD, 155
- Ovulation detection, electrochemical vaginal-oral potentials, 585
- Ovulation inhibition, daily administration of HOE 766 (LH-RH analog), 191
- Paraaminosalicylic acid treatment, interaction of ethinyl estradiol + norethisterone acetate, 617
- Pelvic inflammatory disease, effect of progesterone-releasing IUD, 491
- PGF $2\alpha$  (prostaglandin F $2\alpha$ )
- Pharmacokinetic properties,
  - estradiol benzoate, 415
  - estradiol cypionate, 415
  - estradiol esters, 415
  - estradiol valerate, 415
- Pharmacokinetics,
  - ethinylestradiol, 1, 145
  - mestranol, 17
- Pharmacokinetics of ethinylestradiol, effect of Rifampicin, 135
- Phospholipid fractionation,
  - effect of depot-medroxyprogesterone acetate, 479
  - effect of norethisterone oenanthate, 479
- Plantago ovata*, use in cervical dilator Isapient, 29
- Plasma alpha-feto protein levels, effect of oral contraceptive use, 53
- Plasma concentrations of levonorgestrel, levonorgestrel-releasing IUD, 225
- Plasma levels,
  - ethinylestradiol, 1
  - mestranol, 17
- Platelet aggregation,
  - effect of oral levo-norgestrel + monthly testosterone enanthate (male), 631
  - effect of oral levo-norgestrel + testosterone (male), 381
- Platelet function, effect of oral contraceptives containing 50  $\mu$ g estrogen, 505
- Population difference,
  - plasma levels and pharmacokinetics of ethinylestradiol, 1
  - plasma levels and pharmacokinetics of mestranol, 17
- Postabortal insertion, Nova T and copper T 200 comparative study, 321
- Postmenstrual insertion, Nova T and copper T 200 comparative study, 321
- Pregnancy,
  - effect of ORF 5513 (rat), 529
  - effect of progesterone-releasing IUD, 491
- Pregnancy and implantation, effect of male treated with Gossypol acetic acid (rabbit), 461

## CONTRACEPTION

- Pregnancy interruption, two 15-ME-PGF<sub>2α</sub> suppositories, 273
- Pregnancy termination,
  - dilatation of cervix prior to vacuum aspiration with 15-methyl-PGF<sub>2α</sub> methyl ester, 571
  - effect of Trichosanthin (mouse, rabbit), 77
  - use of cervical dilator Isaptent, 29
- Pre-ovulatory period detection, use of vaginal probe, 41
- Prevalence of morphologic abnormalities in spontaneous abortions, effect of IUD, 47
- Progesterone level,
  - effect of daily administration of HOE 766 (LH-RH analog), 191
  - effect of hCG during pregnancy (rat), 551
  - effect of injectable norethisterone oenanthate, 299
  - effect of levonorgestrel-releasing IUD, 225
  - effect of LRF-agonist (D-Trp<sup>6</sup>,Pro<sup>9</sup>NET)-LRF and hCG, 471
  - effect of 15-ME-PGF<sub>2α</sub> suppository, 273
  - effect of progesterone-releasing IUD, 311
  - norethisterone minipill, 87
  - norethisterone release from bioabsorbable implant (monkey), 165
  - subcutaneous rods containing levonorgestrel, 595
  - vaginal suppository containing 15(S)-15-methyl-PGF<sub>2α</sub> methyl ester, 353
- Progesterone-releasing IUD,
  - effect on bleeding/pain, 491
  - effect on expulsions, 491
  - effect on pelvic inflammatory disease, 491
  - levels of hCG, 311
  - pregnancies, 491
  - removals, 491
- Prolactin level,
  - effect of oral cyproterone acetate (male), 393
  - large oral dose of ethinylestradiol, 145
- Prostaglandin F<sub>2α</sub> (PGF<sub>2α</sub>)
- Protein, effect of medroxyprogesterone acetate, 283
- Radioimmunoassay of norethisterone oenanthate, 299
- Regional lipid levels of brain, effect of ethinylestradiol + norgestrel (rabbit), 433
- Release of norethisterone, bioabsorbable implant (monkey), 165
- Release rate of levonorgestrel, subcutaneous rods containing levonorgestrel, 595
- Removals, progesterone-releasing IUD, 491
- Reproductive organ weights, effect of male treated with Gossypol acetic acid (rat, hamster), 461
- Rifampicin, effect on pharmacokinetics of ethinylestradiol, 135
- Rifampicin treatment, interaction of ethinyl estradiol + norethisterone acetate, 617
- Rods containing levonorgestrel, clinical and endocrinologic study, 595
- 15(S)-15-methyl-PGF<sub>2α</sub> methyl ester, vaginal suppository for menses induction, 353
- 15(S)-15-methyl-prostaglandin F<sub>2α</sub> (15-ME-PGF<sub>2α</sub>),
  - comparison of one- and two-suppository regimen for early pregnancy interruption, 273

## CONTRACEPTION

- Scrotal heating prior to vasectomy,
  - influence on ascorbic acid concentration (rat), 175
  - influence on sperm granuloma formation (rat), 175
  - influence on testicular activity (rat), 175
  - influence on testicular corticosterone (rat), 175
- Semen characteristics, effect of STS 557 (rabbit), 641
- Seminal fluid analyses, oral cyproterone acetate, 245
- Seminal fructose level, effect of oral cyproterone acetate, 393
- Seminal pH, effect of oral cyproterone acetate, 393
- Seminal vesicles and cyproterone acetate, regulation of male fertility (rat), 183
- Serum levels of contraceptive steroids, effect of different drug delivery systems, 217
- Sexual behavior, effect of STS 557 (male rabbit), 641
- Sexual functioning measurement, male fertility regulation, 121
- Sialic acid content in semen, effect of STS 557 (rabbit), 641
- Species differences, antifertility activity of hCG (mouse, Rat, hamster), 551
- Sperm count,
  - effect of oral cyproterone acetate, 393
  - effect of oral levo-norgestrel + monthly testosterone enanthate, 631
  - effect of oral levo-norgestrel + testosterone, 381
  - effect of oral medroxyprogesterone acetate + methyltestosterone, 365
  - effect of treatment with Gossypol acetic acid (rabbit), 461
- Sperm counts and sperm motility, effect of male treated with Gossypol acetic acid (rat, hamster), 461
- Sperm granuloma formation, influence of scrotal heating prior to vasectomy (rat), 175
- Sperm motility,
  - effect of oral cyproterone acetate, 393
  - effect of oral levo-norgestrel + monthly testosterone enanthate, 631
  - effect of oral medroxyprogesterone acetate + methyltestosterone, 365
- Spermatogenesis,
  - effect of oral cyproterone acetate, 393
  - effect of oral levo-norgestrel + testosterone, 381
- Spontaneous abortions, effect of IUD on morphologic abnormalities, 47
- Steroid receptors, effect of *Lithospermum ruderale*, 199
- STS 557 (17 $\alpha$ -cyanomethyl-17 $\beta$ -hydroxy-estra-4,9(10)-diene-3-one)
- Subcutaneous implant, cyproterone acetate in regulation of male fertility (rat), 183
- Subcutaneous rods containing levonorgestrel, clinical and endocrinologic study, 595
- Subdermal implant,
  - norethisterone, 217
  - norethisterone release from bioabsorbable implant (monkey), 165
  - d-norgestrel, 217
- Susceptibility of pregnancy, subcutaneous injection of hCG (rat), 551
- TCu users, measurement of electrochemical vaginal-oral potentials, 585
- Termination of early pregnancy, two 15-ME-PGF<sub>2 $\alpha$</sub>  suppositories, 273

- Termination of pregnancy,
  - dilatation of cervix prior to vacuum aspiration with 15-methyl-PGF<sub>2α</sub> methyl ester, 571
  - effect of Trichosanthin (mouse, rabbit), 77
  - subcutaneous injection of hCG (rat), 551
  - use of cervical dilator Isapient, 29
- Termination rate,
  - five years experience with copper IUDs in nulliparous women, 335
  - Nova T and Copper T 200 comparative study, 321
- Testicular activity, influence of scrotal heating prior to vasectomy (rat), 175
- Testosterone + levo-norgestrel, oral male contraceptive, 381
- Testosterone cypionate + depot-medroxyprogesterone acetate, acceptability for male fertility regulation, 121
- Testosterone enanthate + levo-norgestrel, clinical evaluation of long-term treatment (male), 631
- Testosterone level,
  - effect of oral cyproterone acetate (male), 245, 393
  - effect of oral levo-norgestrel + monthly testosterone enanthate (male), 631
  - effect of oral levo-norgestrel + testosterone (male), 381
  - effect of oral medroxyprogesterone acetate + methyltestosterone (male), 365
- Testosterone oenanthate + 17α-hydroxyprogesterone caproate, acceptability for male fertility regulation, 121
- Testosterone oenanthate + medroxyprogesterone acetate, acceptability for male fertility regulation, 121
- Thai women, effect of injectable norethisterone oenanthate, 299
- Toxicology, oral cyproterone acetate (male), 245
- Trichosanthin-induced termination of pregnancy (mouse, rabbit), 77
- Trichosanthis kirilowii, abortifacient effects from root extract (mouse, rabbit), 77
- Two-year rates, Nova T and copper T 200 comparative study, 321
- Uterine aspartate aminotransferase activity,
  - effect of ethinylestradiol (rat), 659
  - effect of ethinylestradiol + norgestrel (rat), 659
  - effect of norgestrel (rat), 659
- Vacuum aspiration, dilatation of cervix with 15-methyl-PGF<sub>2α</sub> methyl ester vaginal suppository, 571
- Vaginal 15-ME-PGF<sub>2α</sub> suppositories, early pregnancy interruption, 273
- Vaginal 15-methyl-PGF<sub>2α</sub> methyl ester suppository, dilatation of cervix prior to vacuum aspiration, 571
- Vaginal probe, detection of pre-ovulatory period, 41
- Vaginal 15(S)-15-methyl-PGF<sub>2α</sub> methyl ester suppository, menses induction, 353
- Vaginal-oral electrochemical potentials, changes during menstrual cycle, 585
- Vasectomy,
  - influence of scrotal heating on sperm granuloma formation (rat), 175
  - influence of scrotal heating on testicular activity (rat), 175
- Workshop, effects of contraceptive steroids on serum lipoproteins and cardiovascular disease, 115






VOL. 21 1980  
JANUARY - JUNE  
ISSN 0010-7824

# **CONTRACEPTION**

AN INTERNATIONAL JOURNAL



**DANIEL R. MISHELL, Jr., M.D. — Editor**

***Publisher: GERON-X, INC., LOS ALTOS, CALIF.***

# EDITOR

Daniel R. Mishell, Jr., M.D.  
Dept. of Obstetrics and Gynecology  
University of Southern California School of Medicine  
1240 North Mission Road  
Los Angeles, California 90033

# EDITORIAL ASSISTANT

Elfi J. Martin

# BOARD OF ASSOCIATE EDITORS

Wendy Baldwin, Ph.D.  
Behavioral Sciences Branch  
Center for Population Research  
National Institute of Child Health  
and Human Development  
Bethesda, Maryland 20014

Gerold S. Bernstein, Ph.D., M.D.  
Associate Professor  
Department of Obstetrics and  
Gynecology  
USC School of Medicine  
Los Angeles, California 90033

M.C. Chang, Ph.D., Sc.D.  
Senior Scientist  
Worcester Foundation for  
Experimental Biology  
Shrewsbury, Massachusetts 01545

Philip A. Corfman, M.D.  
Director of Population Research  
National Institute of Child Health  
and Human Development  
Bethesda, Maryland 20014

Ilse Goebelsmann, M.D.  
Director of the Reproductive  
Endocrinology Laboratory  
Women's Hospital  
1240 North Mission Road  
Los Angeles, California 90033

Joseph W. Goldzieher, M.D.  
Director, Division of Clinical  
Sciences  
Southwest Foundation for  
Research and Education  
San Antonio, Texas 78228

Roy O. Greep, Ph.D.  
Director  
Laboratory of Human Reproduc-  
tion & Reproductive Biology  
Harvard Medical School  
45 Shattuck Street  
Boston, Massachusetts 02115

Roy Hertz, M.D., Ph.D.  
Research Professor  
Departments of Pharmacology  
and Obstetrics and Gynecology  
George Washington University  
Medical Center  
Washington, D.C. 20037

William D. Odell, M.D., Ph.D.  
Professor and Chairman  
Department of Medicine  
Harbor General Hospital  
U.C.L.A. School of Medicine  
Torrance, California 90509

C. Alvin Paulsen, M.D.  
Professor of Medicine  
Department of Medicine  
University of Washington  
School of Medicine  
Seattle, Washington 98114

John J. Sciarra, M.D., Ph.D.  
Chief of Staff  
Prentice Women's Hospital and  
Maternity Center  
333 East Superior Street  
Chicago, Illinois 60611

Sheldon Segal, Ph.D.  
Director,  
Population Division  
Rockefeller Foundation  
1133 Avenue of the Americas  
New York, New York 10036

William N. Spellacy, M.D.  
Professor and Head  
Department of Obstetrics  
and Gynecology  
The Abraham Lincoln  
School of Medicine  
University of Illinois  
Medical Center  
840 South Wood Street  
Chicago, Illinois 60612

Howard J. Tatum, Ph.D., M.D.  
Associate Director  
Center for Biomedical Research  
Rockefeller University  
York Avenue & 66th Street  
New York, N.Y. 10021

# Corresponding Editors for CONTRACEPTION

E. Coutinho, M.D.  
Professor  
Department of Biochemistry  
and Obstetrics  
University of Bahia  
Salvador, Bahia, BRAZIL

P. G. Crosignani, M.D.  
Professor Incaricato di  
Endocrinologia Ginecologica  
alla Facoltà di Medicina  
Dell'Università di Milano  
Via Comandante 12  
20122 Milano, ITALY

E. Diczfalusy, M.D.  
Professor  
Reprod. Endocrinology  
Research Unit  
Swedish Med. Research Council  
Karolinska Sjukhuset  
Stockholm 60, SWEDEN

J. Ferin, M.D.  
Professor  
Physiology of Human Reprod.  
Research Unit  
University of Louvain Hosp.  
Louvain, BELGIUM

C. Gual, M.D.  
Instituto Nacional da Nutricion  
Hospital de Enfermedades de la  
Nutricion  
Av. San Fernando y  
Viaducto Tlalpan  
Mexico 22, D.F., MEXICO

I. Hallbrecht, M.D.  
Professor  
Department of Obstetrics  
and Gynecology  
Tel Aviv University Med. School  
Tel Aviv, ISRAEL

J. Hammerstein, M.D.  
Professor  
Abt. Gynaek. Endokrinologie  
Sterilität und Familienplanung  
Freie Universität Berlin  
Hindenburgdamm 30  
1000 Berlin 45  
FED. REP. GERMANY

A. A. Haspels, M.D., Prof.  
Department of Obstetrics  
and Gynecology  
Academic Hospital  
University of Utrecht  
Catharinesingel 101  
Utrecht, NETHERLANDS

T. Luukkainen, M.D.  
Steroid Research Laboratory  
University of Helsinki  
Department of Med. Chemistry  
Siltavuorenpenger 10A  
SF-00170 Helsinki 17,  
FINLAND

J. R. Newton, M.D., Prof.  
Birmingham Maternity Hospital  
Queen Elizabeth Medical Centre  
Edgbaston, Birmingham 15  
ENGLAND

Baori N. Saxena, M.D.  
Deputy Director General  
Indian Council of  
Medical Research  
Anseri Nagar  
New Delhi-110016, INDIA

R. P. Shearman, M.D.  
Professor of Obstetrics  
and Gynecology  
The University of Sydney  
Sydney 2006, N.S.W.  
AUSTRALIA

M. Vessey, M.D.  
Professor, University Dept. of  
Social & Community Med.  
University of Oxford  
8 Keble Road  
Oxford, OX13QN  
ENGLAND

J. Zanartu, M.D.  
Associate Professor  
Department of Experimental  
Fertility  
Universidad de Chile Clinica  
Obstetrica  
Hospital Jose Joaquin Aguirre  
Casilla 6637  
Santiago, CHILE

# CONTRACEPTION

January 1980

Volume 21, Number 1

## Plasma Levels and Pharmacokinetics of Ethynyl Estrogens in Various Populations

I. Ethynylestradiol	
Goldzieher, J.W., Dozier, T.S. and de la Pena, A. ....	1
Plasma Levels and Pharmacokinetics of Ethynyl Estrogens in Various Populations	
II. Mestranol	
Goldzieher, J.W., Dozier, T.S. and de la Pena, A. ....	17
Isaptent — A New Cervical Dilator	
Khanna, N.M., Sarin, J.P.S., Nandi, R.C., Singh, S., Setty, B.S., Kamboj, V.P., Dhawan, B.N., Singh, L., Kutty, D. and Engineer, A.D. ....	29
Detection of the Pre-Ovulatory Period Using a Vaginal Probe in the Home	
Borth, R., Benoit, H.J. and Woolever, C.A. ....	41
The Effect of the Intrauterine Contraceptive Device on the Prevalence of Morphologic Abnormalities in Human Spontaneous Abortions	
Honoré, L.H. ....	47
Plasma Alpha-Feto Protein Levels and Its Relation to Duration of Oral Contraceptive Use	
Babu, S., Ramalakshmi, B.A. and Prema, K. ....	53
STS 557, A New Orally Active Progestin with Antiprogestational and Contragestational Properties in Rabbits	
Oettel, M. and Kurischko, A. ....	61
Further Studies on the Trichosanthin-Induced Termination of Pregnancy	
Lau, I.F., Saksena, S.K. and Chang, M.C. ....	77
Hormonal Effects of the 300µg Norethisterone (NET) Minipill. I. Daily Steroid Levels in 43 Subjects During a Pretreatment Cycle and During the Second Month of NET Administration	
Landgren, B.-M. and Diczfalusy, E. ....	87

CONTRACEPTION is published monthly by Geron-X, Inc.  
Box 1108, Los Altos, California 94022, USA.

© 1980, Geron-X, Inc.

Two Volumes per year  
 Personal Subscription \$ 60  
 Institutional Subscription \$100  
 Add \$7 for surface postage outside USA  
 Add \$16 for airmail USA. Add \$36 for airmail outside USA

Second-class postage paid at Los Altos, Calif. and at additional mailing office.

# CONTRACEPTION

February 1980

Volume 21, Number 2

Effects of Contraceptive Steroids on Serum Lipoproteins and Cardiovascular Disease Scrutinized at Workshop in Bethesda Baggett, B. and Nash, H.A. ....	115
Acceptability of Drugs for Male Fertility Regulation: A Prospectus and Some Preliminary Data WHO Task Force on Psychosocial Research in Family Planning .....	121
The Effect of Rifampicin on the Pharmacokinetics of Ethynylestradiol in Women Back, D.J., Breckenridge, A.M., Crawford, F.E., Hall, J.M., MacIver, M., Orme, M.L'E., Rowe, P.H., Smith, E. and Watts, M.J. ....	135
The Pharmacokinetics of a Large (3 mg) Oral Dose of Ethynylestradiol in Women Back, D.J., Bolt, H.M., Breckenridge, A.M., Crawford, F.E., Orme, M.L'E., Rowe, P.H. and Schindler, A.E. ....	145
Patterns of Ovulation and Bleeding with a Low Levonorgestrel-Releasing Intrauterine Device Nilsson, C.G., Lähteenmäki, P. and Luukkainen, T. ....	155
Release of Norethisterone from a Bioabsorbable Implant in Female Bonnet Monkeys ( <i>Macaca radiata</i> ) Maitra, A., Joshi, U.M., Kholkute, S.D., Munshi, S.R., Gupta, G.N. and Tejuja, S. ....	165
The Influence of Scrotal Heating Prior to Vasectomy on Sperm Granuloma Formation and Testicular Activity Subhas, T. and Michaels, T. ....	175
Cyproterone Acetate and Seminal Vesicles in the Regulation of Male Fertility Nayyar, S.K. and Ghosh, T. ....	183
Ovulation Inhibition by Daily I.M. Administration of a Highly Active LH-RH Analog (D-Ser(TBU) <sup>6</sup> -LH-RH-(1-9)-Nonapeptide-Ethylamide) Baumann, R., Kuhl, H., Taubert, H.-D. and Sandow, J. ....	191
The Antigonadotropic Activity of <u>Lithospermum ruderales</u> . I. The Lack of Steroid-Like Activity at the Receptor Level Findley, W.E. and Jacobs, B.R. ....	199

# CONTRACEPTION

March 1980

Volume 21, Number 3

A Randomized, Single Blind Comparative Trial of Norethindrone Enanthate and Depo-Medroxyprogesterone Acetate in Bangladesh Swenson L., Khan, A.R. and Jahan, F.A. ....	207
Release of 19-Nor-Testosterone Type of Contraceptive Steroids Through Different Drug Delivery Systems into Serum and Breast Milk of Lactating Women Toddywalla, V.S., Mehta, S., Virkar, K.D. and Saxena, B.N. ....	217
Levonorgestrel Plasma Concentrations and Hormone Profiles After Insertion and After One Year of Treatment with a Levonorgestrel-IUD Nilsson, C.G., L��hteenm��ki, P. and Luukkainen, T. ....	225
Disposable Menstrual Regulation Kits in a Non-Throw-Away Economy Fortney, J.A. and Vengadasalam, D. ....	235
Use of Low-Dosage Oral Cyproterone Acetate As a Male Contraceptive Wang, C. and Yeung, K.K. ....	245
Early Pregnancy Interruption with Two 15-ME-PGF <sub>2a</sub> Suppositories Lauersen, N.H. and Wilson, K.H. ....	273
Effects of Medroxyprogesterone Acetate on Serum Lipids, Protein, Glucose Tolerance and Liver Function in Thai Women Amatayakul, K., Sivassomboon, B. and Singkamani, R. ....	283
The Effect of Injectable Norethisterone Oenanthate on Ovarian Hormones in Thai Women Werawatgoompa, S., Vaivanijkul, B., Leepipatpaiboon, S., Channiyom, K., Virutamasen, P. and Dusitsin, N. ....	299
Levels of HCG in Subjects Using the Progestasert <sup>TM</sup> Intrauterine Progesterone Systems Custo, G.M., Carenza, L. and Pala, A. ....	311

# CONTRACEPTION

April 1980

Volume 21, Number 4

Two-Year Rates for Nova T and Copper T in a Comparative Study Allonen, H., Luukkainen, T., Nielsen, N.-C., Nygren, K.-G. and Pyörälä, T. ....	321
Five Years Private Practice Experience of Nulliparous Women Using Copper IUD's Smith, R.P., Goresky, D.M. and Etchell, D.M. ....	335
Quantitative Menstrual and Intermenstrual Blood Loss in Women Using Lippes Loop and Copper T Intrauterine Devices Shaw, S.T., Jr., Andrade, A.T.L., de Souza, J.P., Macaulay, L.K. and Rowe, P.J. ....	343
Analysis of a Study of Menses Induction Using a Vaginal Suppository Containing 3.0 mg 15(S)-15-Methyl-PGF <sub>2α</sub> Methyl Ester Spilman, C.H., Gutknecht, G.D., Beuving, D.C. and Southern, E.M. ....	353
The Combined Use of Oral Medroxyprogesterone Acetate and Methyltestosterone in a Male Contraceptive Trial Programme Bain, J., Rachlis, V., Robert E. and Khait, Z. ....	365
Oral Levo-Norgestrel - Testosterone Effects on Spermatogenesis, Hormone Levels, Coagulation Factors and Lipoproteins in Normal Men Foegh, M., Damgaard-Pedersen, F., Gormsen, J., Knudsen, J.B. and Schou, G. ....	381
Medium Dose Cyproterone Acetate (CPA): Effects on Hormone Secretion and on Spermatogenesis in Men Moltz, L., Römmler, A., Post, K., Schwartz, U. and Hammerstein, J. ....	393
A Comparison of the Pharmacokinetic Properties of Three Estradiol Esters Oriowo, M.A., Landgren, B.-M., Stenström, B. and Diczfalussy, E. ....	415
Effect of HCG β-TT Immunization on Ovarian Morphology in Hamsters Implanted with Human Choriocarcinoma Knecht, M. ....	425
Microanalysis of Lipids in Discrete Brain Areas of the Rabbit Following Intramuscular Administration of Steroid Contraceptive Islam, F., Hasan, M., Rizvi, R. and Osman, S.M. ....	433

# CONTRACEPTION

May 1980

Volume 21, Number 5

A Randomized, Double-Blind Study of Two Combined Oral Contraceptives Containing the Same Progestogen, But Different Estrogens World Health Organization Task Force on Oral Contraceptives .....	445
Effects of Gossypol on the Fertility of Male Rats, Hamsters and Rabbits Chang, M.C., Gu, Z. (Ku, C-P) and Saksena, S.K. ....	461
Chorionic Gonadotropin Prevents LRF-Agonist-Induced Luteolysis in the Human Casper, R.F., Sheehan, K.L. and Yen, S.S.C. ....	471
Serum Phospholipid Fractionation After the Use of Long-Acting Progestational Contraceptives Guirgis, F.K., El-Sawy, M., Abdel-Hay, M.M., Saleh, F.M. and Abdel-Gawad, A.H.E. ...	479
Selected Events Following Insertion of the Progestasert® System Gibor, Y. and Mitchell, C. ....	491
Effects of Oral Contraceptives Containing 50µg Estrogen on Blood Coagulation in Non-Caucasian Women Tsakok, F.H.M., Koh, S. and Ratnam, S.S. ....	505
Prototype for a New Class of Antifertility Agents, 3,5-Bis (Dimethylamino)-1,2,4,-Dithiazolium Chloride Hahn, D.W., McConnell, R.F. and McGuire, J.L. ....	529
STS 557 As an Interceptive in Rodents and Baboons Oettel, M., Komor, A., Goncharov, N.P., Kurischko, A., Strecke, J. and Schubert, K. ..	537
Studies on the Mechanism of the Antifertility Activity of Human Chorionic Gonadotropin in Rodents Hahn, D.W., Demers, L.M. and McGuire, J.L. ....	551

# CONTRACEPTION

June 1980

Volume 21, Number 6

The Association of Depo-Medroxyprogesterone Acetate and Breast Cancer Greenspan, A.R., Hatcher, R.A., Moore, M., Rosenberg, M.J. and Ory, H.W. ....	563
Dilatation of the Cervix Prior to Vacuum Aspiration By Single Vaginal Administration of 15-Methyl-PGF <sub>2α</sub> Methyl Ester Frankman, O., Bygdeman, M., Green, K., Moberg, P. and Sandberg, C-G .....	571
Actinomyces in the Endometrium of IUD Users Aubert, J.M., Gobeaux-Castadot, M-J and Boria, M.C. ....	577
Electrochemical Vaginal-Oral Potentials During the Menstrual Cycle in Women Zipper, J., Bruzzone, M.E. and Angelo, S. ....	585
Clinical and Endocrinologic Study of Continuous Levonorgestrel administration from Subcutaneous Solid Polydimethylsiloxane Rods Roy, S., Stanczyk, F., Mishell, D.R., Jr., Lumkin, M. and Gentschein, E. ....	595
A Study of Interaction of a Low-Dose Combination Oral Contraceptive with Anti-Tubercular Drugs Joshi, J.V., Joshi, U.M., Sankolli, G.M., Gupta, K., Rao, A.P., Hazari, K., Sheth, U.K. and Saxena, B.N. ....	617
Clinical Evaluation of Long-Term Treatment with Levo-Norgestrel and Testosterone Enanthate in Normal Men Foegh, M., Nichol, K., Petersen, I.B. and Schou, G. ....	631
Effect of STS 557 on Semen Composition, Fertility and Sexual Behaviour of Male Rabbits Freund, H., Hesse, G. and Oettel, M. ....	641
Inhibition of LH-Induced Ovulation in the Rat by a Hormonal Antagonist Sairam, M.R. ....	651
Uterine and Kidney Aspartate Aminotransferase Activity in Ethinylestradiol- and Norgestrel-Treated Rats Williams, S.A. and Boots, L.R. ....	659
Author Index for Volume 21 .....	665
Subject Index for Volume 21 .....	667



## INDEX TO VOLUME 22

## AUTHOR INDEX

- Ahmad, N., 573  
 Akerlund, M., 199  
 Akinla, O., 115  
 Amatayakul, K., 605  
 Annus, J., 9  
 Back, D.J., 495  
 Bates, M., 495  
 Begum, S.F., 573  
 Bergquist, C., 287, 341  
 Betrabet, S., 241  
 Black, T.R.L., 653  
 Bleumink, E., 25  
 Boonsiri, B., 397  
 Bowden, A., 495  
 Bowers, C.Y., 313  
 Brat, T., 9  
 Breckenridge, A.M., 495  
 Bremme, K., 471  
 Brenner, P.F., 85, 137  
 Bressler, R., 597  
 Bruijn, H.W.A., 359  
 Burton, F.G., 409  
 Bygdeman, M., 153, 471  
 Carrillo, D., 259  
 Cates, W., Jr., 513  
 Chenault, C.B., 369  
 Chowdhury, V., 241, 643  
 Chretien, F.C., 445  
 Christensen, N., 153, 471  
 Christian, C.D., 597  
 Chvapil, M., 325  
 Croxatto, H.B., 259, 583  
 Croxatto, H.-D., 259  
 Dagle, G.E., 409  
 Dawson, A.G., 505  
 de Gaetano, G., 249  
 de Gast, G.C., 25  
 Diaz, S., 259, 583  
 Dickerson, J., 597  
 Diethelm, P., 9  
 di Minno, G., 249  
 Dombrowicz, N., 537  
 Donati, M.B., 249  
 Dreyer, N.A., 123  
 Droegenmueller, W., 325  
 Dukes, M., 383  
 Edgren, R.A., 39  
 Elamsson, K., 583  
 El-Habashi, M., 549  
 El-Mahgoub, S., 271  
 El-Sahwi, S., 549  
 Englund, D., 71  
 Eskelson, C.D., 325  
 Folkers, K., 313  
 Fong, H.H.S., 183  
 Forshell, S., 383  
 Fotherby, K., 527  
 Free, M.J., 31  
 Friebe, K., 313  
 Gawish, S., 549  
 Gerretsen, G., 25  
 Gill, B.P., 63  
 Gillman, S., 295  
 Goebelsmann, U., 85, 457  
 Goh, T.H., 389  
 Goldstuck, N.D., 653  
 Goldzieher, J.W., 369  
 Gopalkrishna, K., 241  
 Göser, R., 165  
 Gray, R.H., 9  
 Gréen, K., 153, 471  
 Gupta, K., 643  
 Gutknecht, G., 57  
 Hahnenberger, R., 349  
 Hall, M.J., 495  
 Hamberger, L., 383  
 Hansen, P.R., 369  
 Hariharan, M., 389  
 Haspels, A.A., 441  
 Hazari, K., 643  
 Heywood, R., 189  
 Hindriks, F.R., 359  
 Howe, G.R., 175  
 Huang, D.C., 623  
 Hdmpel, M., 485  
 Humphrey, R.R., 39  
 Humphries, J., 313  
 Hutton, P., 505  
 Jänne, O., 19  
 Johansson, E.D.B., 349, 583  
 Jones, A.R., 505  
 Jones, D.C., 39

## CONTRACEPTION

- Jones, H., 495  
 Jones, W.R., 425  
 Jordan, J.H., 39  
 Joshi, J.V., 643  
 Joshi, U.M., 241, 643  
 Källfelt, B., 383  
 Kankeerati, W., 397  
 Keller, E., 165  
 Koetsawang, S., 527  
 Kremer, J., 25, 359  
 Krishna, U., 643  
 Ladanyi, S., 165  
 Laudanski, T., 199  
 Lewis, D.J., 189  
 Liao, W.C., 573  
 Lopes, A., 9  
 Lundström, V., 153, 471  
 MacIver, M., 495  
 Mandlekar, A., 643  
 Marrs, R.P., 137  
 Mathrubutham, M., 527  
 Matin, S., 457  
 Mehta, S., 241  
 Miranda, P., 583  
 Mishell, D.R., Jr., 85, 137  
 Morrow, M.M., 31  
 Mussoni, L., 249  
 McCann, M.F., 573  
 McDaniel, E.R., 1  
 Nater, J.P., 25  
 Neau, C., 445  
 Nerenberg, C., 457  
 Newton, J., 9  
 Newton, J.R., 295  
 Nillius, S.J., 287, 341  
 Nilsson, O., 71  
 Nitichai, Y., 397  
 Ohman, L., 349  
 Orme, M., 495  
 Osman, M., 549  
 Owen, J.A., 325  
 Oyediran, M.A., 115  
 Paavonen, J., 107  
 Pangrazzi, J., 249  
 Parker, R.A., 1  
 Pastushok, C.A., 39  
 Pavez, M., 259  
 Pei-Zhu, Z., 561  
 Perucca, E., 495  
 Pholpramool, C., 673  
 Pizarro, E., 9  
 Pizzo, S.V., 123  
 Querido, L., 441  
 Quinteros, E., 259  
 Rainer, E., 485  
 Reel, J.R., 39  
 Reyers, I., 249  
 Richens, A., 495  
 Rienprayura, D., 397  
 Roncaglioni, M.C., 249  
 Rosati, S., 259  
 Roux, J.F., 57  
 Rowe, P.H., 495  
 Rowe, S.E., 409  
 Roy, S., 137  
 Sakowski, R., 39  
 Sankholi, G.M., 643  
 Saxena, B.N., 241, 643  
 Schindler, A.E., 165  
 Schircks, B., 313  
 Schneider, B.E., 369  
 Scholz, I., 9  
 Schulz, K.F., 513  
 Schwallie, P.C., 623  
 Shain, R.N., 213, 227  
 Sheth, U.K., 643  
 Sikov, M.R., 409  
 Simonetti, L., 259  
 Sivasomboon, B., 605  
 Skiens, E.W., 31  
 Skiens, W.E., 409  
 Smith, E., 495  
 Sornpaisarn, L., 673  
 Southern, E., 57  
 Spence, A., 653  
 Stanczyk, F.Z., 85, 457  
 Steward, R., 175  
 Stiffel, V., 325  
 Stoppelli, I., 485  
 Sureau, C., 445  
 Tan, C.H., 389  
 Tangkeow, P., 397  
 Thanangkul, O., 605  
 The, T.H., 25  
 Turner, L.F., 623  
 Umapathysivam, K., 425

## CONTRACEPTION

Van de Walle, J., 537  
Vesterinen, E., 107  
Victor, A., 71  
Virutamasen, P., 397  
Voda, A.M., 63  
Wadsworth, P.F., 189  
Waller, D.P., 183  
Weiner, E., 71  
Wide, L., 287, 341

Wilde, K., 63  
Wilks, J.W., 313  
Williams, W.L., 659  
Wilson, E.W., 9  
Windsor, B.L., 39  
Woutersz, T.B., 369  
Ylöstalo, P., 19  
Zaneveld, L.J.D., 183



## INDEX TO VOLUME 22

### SUBJECT INDEX

- Abnormalities found on pelvic examination, intramuscular  
  prostaglandin for failure of mid-trimester abortion  
  by another method, 623
- Abortion, oxytocin augmentation during second-trimester, 513
- Abortion population, incidence of gonorrhea, 441
- Activated factor X inhibitor activity, mestranol + lynestrenol  
  (rat), 249
- Acute salpingitis patients,  
  use of IUD, 107
- use of oral contraceptives, 107
- Adverse reactions, intramuscular prostaglandin for failure  
  of mid-trimester abortion by another method, 623
- Agonist of LHRH,  
  effect on luteal function, 287
- inhibition of preovulatory gonadotropin secretion  
  (monkey), 313
- luteolysis prevented by HCG, 341
- Alkylating agents, use in male fertility regulation (rat,  
  hamster), 175
- Ampicillin therapy, interaction with ethinyl estradiol +  
  norethisterone acetate, 643
- Antagonistic analogues of LHRH, biological effects (rat,  
  hamster, rabbit), 39
- Anthropometric studies, DMPA users, 605
- Anticonvulsant therapy, interaction with ethynylestradiol  
  + levonorgestrel, 495
- Antithrombin III activity, mestranol + lynestrenol (rat),  
  249
- Antithrombin-III level, women with history of idiopathic  
  thromboembolism, 123
- Biochemical and protein composition of endometrium, effects  
  of contraceptive agents, 425
- Biological effects of antagonistic analogues of LHRH (rat,  
  hamster, rabbit), 39
- Bleeding pattern,  
  clinical effects of ethinyl estrogens with and without  
  progestational agents, 369
- effect of medroxyprogesterone acetate, 527
- Blood and cerebrospinal fluid levels of 17 $\beta$ -estradiol, after  
  ocular and nasal administration (monkey), 349
- Blood coagulation and idiopathic thromboembolism, 123
- Blood levels of 17 $\beta$ -estradiol, after ocular administration,  
  349
- Blood pressure,  
  clinical effects of ethinyl estrogens with and without  
  progestational agents, 369
- effect of mestranol + lynestrenol (rat), 249

## CONTRACEPTION

- Body and organ weights, effect of LHRH antagonistic analogues (rat), 39
- Body water compartmentalization studies, DMPA users, 605
- Burst test parameters, measurement of condom strength, 31
- Castration,
  - effect on electrolyte composition of cauda epididymal plasma (rat), 673
  - effect on electrolyte composition of epididymal spermatozoa (rat), 673
  - effect on fertility (rat), 673
- Cauda epididymal plasma, electrolyte composition after castration (rat), 673
- Cell-mediated immunity, effect of hormonal contraceptives, 25
- Cerebrospinal fluid and blood levels of 17 $\beta$ -estradiol, after ocular and nasal administration (monkey), 349
- Cervical dilatation,
  - effect of 9-deoxo-16,16-dimethyl-9-methylene-PGE<sub>2</sub>, 153
  - use of prostaglandin E analogues, 471
- Cervical mucus,
  - effect of d-norgestrel-releasing intracervical device (primate), 409
  - effect of norgestrienone, 445
- $\alpha$ -Chlorohydrin (3-chloropropan-1,2-diol)
  - inhibition of glycolysis in sperm (boar), 505
- Clinical effects of ethynyl estrogens on bleeding patterns, weight and blood pressure, 369
- Clinical effects of ethynyl estrogens + progestational agents on bleeding patterns, weight and blood pressure, 369
- Clinical laboratory findings, d-norgestrel-releasing intracervical device (primate), 409
- Clinical performance,
  - noregestrel-T IUD, 271
  - Nova-T and copper-T-200, 115
- Clinical study,
  - ethinyloestradiol and ethinyloestradiol + lynestrenol, 537
  - norethisterone oenanthate, 397
- Clinical trial, Neo Sampooon vaginal contraceptive tablets, 573
- Combined oral contraceptives, effect on nucleic acid and protein composition of endometrial tissue, 425
- Commercial vaginal contraceptives, improvement of efficacy with zinc (rabbit), 659
- Comparative multicentre trial, IUDs inserted immediately following delivery of placenta, 9
- Comperative study, clinical performance of Nova-T and copper-T-200, 115
- Complication and treatment rates during second-trimester abortion, effect of oxytocin augmentation, 513
- Complications post-sterilization, retrospective survey, 295
- Condom strength and relationship to failure during use, 31

- Copper 7,
  - post-coital insertion, 653
  - post-placental insertion, 9
- Copper IUD, effect on nucleic acid and protein composition of endometrial tissue, 425
- Copper-bearing IUDs, effect on serum iron indices and haemoglobin concentration, 389
- Copper-releasing IUDs, Nova-T and copper-T-200, 115
- Copper-T-200,
  - clinical performance, 115, 271
  - five years experience, 561
  - gross appearance of IUD after five years of use, 561
  - histological changes of endometrium, 561
  - loss of copper from IUD, 561
  - post-abortion insertion, 561
- Creatinine excretion, DMPA users, 605
- Cyproterone acetate (17-acetoxy-6-chloro-1 $\alpha$ -2 $\alpha$ -methylene-4,6-pregnadiene-3,20-dione)
  - plasma concentration, 485
  - transfer to milk during lactation, 485
- Decidual cells, ultrastructural features after levonorgestrel-releasing intravaginal ring (monkey), 189
- 9-Deoxo-16,16-dimethyl-9-methylene-PGE<sub>2</sub>,
  - effect on uterine contractility, 153
  - vaginal suppository for dilatation of cervix, 471
  - vaginal suppository for mid-trimester abortion, 153
  - vaginal suppository for termination of early pregnancy, 471
- Depot-medroxyprogesterone acetate (DMPA) (see also Medroxyprogesterone acetate)
  - effect on serum high density lipoprotein cholesterol levels, 359
  - use of quinesterol for control of vaginal bleeding irregularities, 1
- Different doses of medroxyprogesterone acetate, pharmacokinetic study, 527
- Dilatation of cervix,
  - effect of 9-deoxo-16,16-dimethyl-9-methylene-PGE<sub>2</sub>, 153
  - use of prostaglandin E analogues, 471
- Distribution, nonoxynol-9 (rabbit), 325
- DMPA (depot-medroxyprogesterone acetate)
- Duration of efficacy, norgestrienone, 445
- Early gestation termination, single vaginal suppository of (15S)-15-methyl-PGF<sub>2</sub> $\alpha$  methyl ester, 137
- Early pregnancy termination,
  - single vaginal suppository of 15(S)-15-methyl PGF<sub>2</sub> $\alpha$  (methyl ester), 57
  - use of prostaglandin E analogues, 471
- Ectopic pregnancy, association with progestagen-releasing IUDs, 259
- Efficacy of intramuscular prostaglandin for failure of mid-trimester abortion by another method, 623

## CONTRACEPTION

- Electrolyte composition,
  - cauda epididymal fluid after castration (rat), 673
  - epididymal spermatozoa after castration (rat), 673
- Endometrial changes, norgestrel-T IUD, 271
- Endometrial effects, estradiol and levonorgestrel, 71
- Endometrial estrogen and progesterone receptors, effect of progesterone-releasing IUD, 19
- Endometrium, effects of contraceptive agents on biochemical and protein composition, 425
- Epididymal spermatozoa, effect on electrolyte composition after castration (rat), 673
- Escape ovulation due to missing pill intake, ethinyl estradiol + norethisterone acetate, 241
- Estradiol, effects on endometrium, 71
- 17 $\beta$ -Estradiol,
  - levels in blood and cerebrospinal fluid after ocular and nasal administration (monkey), 349
  - levels in blood after ocular administration, 349
- Estradiol and levonorgestrel, effects on endometrium, 71
- Estradiol-benzoate + estradiol-phenylpropionate, effect on plasma hormone concentrations, 165
- postcoital contraception, 165
- Estrogen receptors, effect of progesterone-releasing IUD, 19
- Estrous cycle, effect of LHRH antagonistic analogues (rat), 39
- Ethinylestradiol,
  - pharmacodynamics, 85
  - pharmacokinetics, 457
  - radioimmunoassay in presence of circulating norethindrone, 457
- Ethinylestradiol + norethindrone,
  - effect on liver function tests, 597
  - pharmacodynamics of ethinylestradiol, 85
  - radioimmunoassay of ethinylestradiol, 457
- Ethinyl estradiol + norethisterone acetate,
  - effect on plasma level of Ampicillin, 643
  - effect on plasma level of Metronidazole, 643
  - escape ovulation due to missing pill intake, 241
  - interaction with Ampicillin and Metronidazole, 643
- Ethinylestradiol + norgestrel, pharmacodynamics of ethinylestradiol, 85
- Ethinylestradiol concentrations, following ethinylestradiol + norethindrone, 457
- Ethinyl estradiol plasma level, effect of Ampicillin and Metronidazole treatments, 643
- Ethinylestradiol single oral dose, pharmacodynamics of ethinylestradiol, 85
- Ethinylestradiol + lynestrenol and ethinylestradiol, clinical, histological and stereomorphometric studies, 537
- Ethinylestradiol + d-norgestrel, influence on cell-mediated immunity, 25



## CONTRACEPTION

- Ethinylestradiol and ethinylestradiol + lynestrenol,  
clinical, histological and stereomorphometric studies, 537
- oral contraceptive of normophasic type, 537
- Ethinylestradiol and ethinylestradiol + mestranol acetate,  
influence on cell-mediated immunity, 25
- Ethinylestradiol, clinical effects on bleeding patterns,  
weight and blood pressure, 369
- Ethinylestradiol + levonorgestrel, interaction of pheno-  
barbital and other anticonvulsants, 495
- Ethinylestradiol + megestrol acetate, clinical effects on  
bleeding patterns, weight and blood pressure, 369
- Ethinylestradiol + norethindrone acetate, clinical effects  
on bleeding patterns, weight and blood pressure, 369
- Ethinylestradiol + norethisterone acetate, interaction of  
phenobarbital and other anticonvulsants, 495
- Ethinylestradiol + dl-norgestrel, clinical effects on  
bleeding patterns, weight and blood pressure, 369
- Ethinylestradiol levels, interaction of phenobarbital and  
other anticonvulsants, 495
- Excretion, nonoxynol-9 (rat, rabbit), 325
- Failure during use, relationship to strength of condoms, 31
- Failure of mid-trimester abortion by another method, use of  
intramuscular (15S)-15-methyl PGF<sub>2α</sub>, 623
- Fallopian tubes, effect of Lippes loop on sperm recovery, 549
- Fertility, effect of castration (rat), 673
- Fibrinolytic activity,  
mestranol + lynestrenol (rat), 249
- women with history of idiopathic thromboembolism, 123
- First trimester pregnancy, uterine effects of vasopressin  
analogue, 199
- Five years experience, Copper T 200, 561
- Five years of use, levonorgestrel subdermal implants, 583
- Foaming vaginal insert, contraceptive effect (rabbit), 659
- Foaming vaginal tablets, clinical trial of Neo Sampooon, 573
- Glycolysis inhibition in sperm, α-chlorohydrin (boar), 505
- Gonadotropin secretion inhibition during preovulatory phase  
by LHRH agonist (monkey), 313
- Gonorrhea, incidence in abortion population, 441
- Gossypol,  
contraceptive effect (rabbit), 659
- spermicidal activity, 183
- Gossypol acetic acid, spermicidal activity, 183
- Gossypol-polyvinylpyrrolidone, spermicidal activity, 183
- Gross appearance of TCu 200 after five years of use, 561
- Haemoglobin concentration, effect of copper-bearing IUDs, 389
- HCG (human chorionic gonadotropin)
- HCG β-subunit level, use of 15(S)-15-methyl PGF<sub>2α</sub> (methyl  
ester), 57
- HCG levels, use of prostaglandin E analogues, 471

## CONTRACEPTION

- HCG prevents luteolysis induced by LHRH agonist, 341
- hCG levels, use of (15S)-15-methyl-PGF<sub>2α</sub> methyl ester, 137
- Hemostatic system, effect on plasmatic and vascular factors  
by mestranol + lynestrenol (rat), 249
- High density lipoprotein cholesterol levels, effect of  
DMPA, 359
- Histological changes of endometrium, TCu 200, 561
- Histological study, ethinyloestradiol and ethinyloestradiol  
+ lynestrenol, 537
- Histopathological findings, d-norgestrel-releasing intra-  
cervical device (primate), 409
- Hormonal contraceptives, effect on immune reactivity, 25
- Hormone concentrations, after postcoital contraception  
with estradiol-benzoate + estradiol-phenylpro-  
pionate, 165
- Human chorionic gonadotropin (HCG)
- Hypertonic saline, effect of oxytocin augmentation, 513
- Idiopathic thromboembolism,  
Antithrombin-III level, 123  
fibrinolytic activity, 123
- Idiopathic thromboembolism and blood coagulation, 123
- Immune reactivity, effect of hormonal contraceptives, 25
- Impact of reversibility on selection of tubal sterilization,  
27
- Implant contraception, levonorgestrel, 583
- Incidence of gonorrhea in abortion population, 441
- Inert IUD, effect on nucleic acid and protein composition  
of endometrial tissue, 425
- Infrastructure of cervical mucus, effect of norgestrienone,  
445
- Inhibition of glycolysis in sperm, α-chlorohydrin (boar), 505
- Inhibition of preovulatory gonadotropin secretion by LHRH  
agonist (monkey), 313
- Injectable contraceptive,  
depot-medroxyprogesterone acetate, 1, 359  
medroxyprogesterone acetate, 25, 527, 605  
norethisterone oenanthate, 397
- Intracervical device, d-norgestrel-releasing (primate), 409
- Intrauterine device (IUD)  
copper, 425  
copper 7, 9, 389, 653  
copper-T-200, 115, 259, 271, 561  
inert, 425  
levonorgestrel-releasing, 259, 271  
Lippes loop size D, 9  
Lippes loop type C, 549  
megestrol acetate-releasing, 259  
Multiload 250, 389  
norethindrone-releasing, 259

## CONTRACEPTION

- norgestrel T, 271
- norgestrienone-releasing, 259
- Nova-T, 115
- post-partum copper T, 9
- post-placental insertion, 9
- progesterone-releasing, 19
- R2323-releasing, 259
- T-220C, 389
- use in patients with acute salpingitis, 107
- Intravaginal ring,
  - estradiol- and levonorgestrel-releasing, 71
  - levonorgestrel-releasing, 71
  - levonorgestrel-releasing (monkey), 189
- Iron indices, effect of copper-bearing IUDs, 389
- IUD (intrauterine device)
- IUD insertion, post-coital, 653
- Lactation,
  - appearance of nonoxynol-9 in milk (rat), 325
  - transfer of cyproterone acetate in milk, 485
- Laparoscopy sterilization, analysis of morbidity and post-sterilization complications, 295
- Laparotomy sterilization, analysis of morbidity and post-sterilization complications, 295
- Levonorgestrel,
  - effects on endometrium, 71
  - radioimmunoassay, 583
  - subdermal implants, 583
- Levonorgestrel levels, following implantation of silastic capsules containing levonorgestrel, 583
- Levonorgestrel-releasing intravaginal ring, ultrastructural study of decidual cells (monkey), 189
- Levonorgestrel-releasing IUD,
  - association with ectopic pregnancy, 259
  - clinical performance, 271
  - endometrial changes, 271
  - menstrual pattern, 271
  - quantitation of menstrual blood loss, 271
- LHRH (luteinizing hormone releasing hormone)
- LHRH agonist,
  - effect on luteal function, 287
  - inhibition of preovulatory gonadotropin secretion (monkey), 313
- LHRH agonist-induced luteolysis prevented by HCG, 341
- LHRH analogue,
  - Boc-[Ser(Bzl)<sup>1</sup>, des-His<sup>2</sup>, D-Trp<sup>6</sup>]-LHRH, 39
  - D-Ser(TBU)<sup>6</sup>-EA<sup>10</sup>-LRH, 287, 41
  - [(Glu-Pro)<sup>1</sup>, D-Phe<sup>2</sup>, D-Trp<sup>3,6</sup>]-LHRH, 313
  - Z-[Gln<sup>1</sup>, des-His<sup>2</sup>, D-Pse<sup>6</sup>, des-Gly<sup>10</sup>]-LHRH ethylamide, where D-Pse=threo-D-phenylserine, 39
- LHRH antagonistic analogues, biological effects (rat, hamster, rabbit), 39

## CONTRACEPTION

- Lippes loop,
  - effect on recovery of sperm from fallopian tubes, 549
  - effect on white blood corpuscles in tubal washings, 549
- Lippes loop size D, post-placental insertion, 9
- Liver function tests, effect of ethinyl estradiol + norethindrone, 597
- Long-term levonorgestrel subdermal implants, plasma levels of levonorgestrel, 583
- Loss of copper from TCU 200 after five years of use, 561
- Luminal ethelium, endometrial effects of estradiol and levonorgestrel, 71
- Luteal function, effect of LHRH agonist, 287
- Luteal phase institution of LHRH agonist treatment, 287
- Luteinizing hormone releasing hormone (LHRH)
- Luteolysis induced by LHRH agonist prevented by HCG, 341
- Luteolytic effect, PGF<sub>2</sub> $\alpha$  analogue in non-pregnant women, 383
- 8-Lysine-vasopressin, uterine effects in first trimester pregnancy, 199
- Male fertility regulation, use of alkylating agents (rat, hamster), 175
- Malondialdehyde generation, mestranol + lynestrenol (rat), 249
- Manganese, contraceptive effect (rabbit), 659
- Mechanism of weight gain, DMPA users, 605
- Medroxyprogesterone acetate (see also Depot-medroxyprogesterone acetate)
  - anthropometric studies, 605
  - body water compartmentalization studies, 605
  - creatinine excretion, 605
  - effect on bleeding pattern, 527
  - effect on ovarian function, 527
  - influence on cell-mediated immunity, 25
  - mechanism of weight gain, 605
  - nitrogen balance study, 605
  - pharmacokinetic study of different doses, 527
- Megestrol acetate-releasing IUD, association with ectopic pregnancy, 259
- Menstrual blood loss, norgestrel-T IUD, 271
- Menstrual cycle, serum phosphorus levels, 63
- Menstrual pattern, norgestrel-T IUD, 271
- Menstrual regulation, use of prostaglandin E analogues, 471
- Mestranol, clinical effects on bleeding patterns, weight and blood pressure, 369
- Mestranol + lynestrenol, effect on plasmatic and vascular factors of hemostatic system (rat), 249
- Mestranol + megestrol acetate, clinical effects on bleeding patterns, weight and blood pressure, 369
- Mestranol + norethindrone, pharmacodynamics of ethinyl-estradiol, 85
- Mestranol + norethindrone acetate, clinical effects on bleeding patterns, weight and blood pressure, 369
- Mestranol + dl-norgestrel, clinical effects on bleeding patterns, weight and blood pressure, 369

## CONTRACEPTION

- Metabolic study, norethisterone oenanthate, 397
- Metabolism, nonoxynol-9 (rabbit), 325
- Metronidazole therapy, interaction with ethinyl estradiol + norethisterone acetate, 643
- Mid-trimester abortion,
  - use of 9-deoxo-16,16-dimethyl-9-methylene-PGE<sub>2</sub> suppository, 153
  - use of intramuscular (15S)-15-methyl PGF<sub>2</sub> $\alpha$  for failure of another method, 623
- Milk,
  - appearance of nonoxynol-9 during lactation (rat), 325
  - transfer of cyproterone acetate during lactation, 485
- Missing pill intake, escape ovulation during treatment
  - with ethinyl estradiol + norethisterone acetate, 241
- Morbidity post-sterilization, retrospective survey, 295
- "Morning after" injection, estradiol-benzoate + estradiol-phenylpropionate, 165
- Multicentre trial, IUDs inserted immediately following delivery of placenta, 9
- Myometrial effects of vasopressin analogue in first trimester pregnancy, 199
- N- $\alpha$ -triglycyl-(8-lysine)-vasopressin, uterine effects in first trimester pregnancy, 199
- Nasal administration of 17 $\beta$ -estradiol, levels in blood and cerebrospinal fluid (monkey), 349
- Neo Sampoo (active ingredient, p-methanylphenyl polyoxyethylene (8.8) ether)
- Neo Sampoo vaginal contraceptive tablets, clinical trial, 573
- Nitrogen balance study, DMPA users, 605
- Nonoxynol-9 (nonylphenoxypoly (ethyleneoxy) ethanol)
  - intravaginal absorption, distribution, metabolism and excretion (rat, rabbit), 325
- Non-pregnant women, luteolytic effect of PGF<sub>2</sub> $\alpha$  analogue, 383
- Norethindrone, pharmacokinetics, 457
- Norethindrone concentrations, following ethinylestradiol + norethindrone, 457
- Norethindrone removal before radioimmunoassay of ethinyl-estradiol, 457
- Norethindrone-releasing IUD, association with ectopic pregnancy, 259
- Norethisterone oenanthate, clinical and metabolic study, 397
- Norethisterone plasma level, effect of Ampicillin and Metronidazole treatments, 643
- d-Norgestrel-releasing intracervical device,
  - clinical laboratory findings (primate), 409
  - effect on cervical mucus (primate), 409
  - effect on serum progesterone levels (primate), 409
  - gross and histopathological findings (primate), 409
- Norgestrel-T IUD, clinical performance, 271

## CONTRACEPTION

- Norgestrienone,
  - duration of efficacy, 445
  - effect on infrastructure of cervical mucus, 445
  - effect on spermatozoa, 445
- Norgestrienone-releasing IUD, association with ectopic pregnancy, 259
- Normophasic contraceptive, ethinyloestradiol and ethinyl-oestradiol + lynestrenol, 537
- Nova-T IUD, clinical performance, 115
- Nucleic acid and protein composition of endometrial tissue,
  - use of combined oral contraceptives, 425
  - use of copper IUD, 425
  - use of inert IUD, 425
- Objections concerning permanent sterilization, 213
- Objections concerning reversible sterilization, 213
- Objections to tubal sterilization, what reversibility can and cannot overcome, 213
- Occlusion times of aortic loop, mestranol + lynestrenol (rat), 249
- Ocular administration of 17 $\beta$ -estradiol,
  - levels in blood, 349
  - levels in blood and cerebrospinal fluid (monkey), 349
- Oral contraceptive,
  - combination type, 425
  - ethinyl estradiol + norethindrone, 85, 597
  - ethinyl estradiol + norethisterone acetate, 241, 643
  - ethinylestradiol + norgestrel, 85
  - ethinyloestradiol + d-norgestrel, 25
  - ethinyloestradiol and ethinyloestradiol + lynestrenol, 537
  - ethinyloestradiol and ethinyloestradiol + mestranol acetate, 25
  - ethinylestradiol, 369
  - ethinylestradiol + levonorgestrel, 495
  - ethinylestradiol + megestrol acetate, 369
  - ethinylestradiol + norethindrone acetate, 369
  - ethinylestradiol + norethisterone acetate, 495
  - ethinylestradiol + dl-norgestrel, 369
  - mestranol, 369
  - mestranol + megestrol acetate, 369
  - mestranol + norethindrone, 85
  - mestranol + norethindrone acetate, 369
  - mestranol + dl-norgestrel, 369
  - norgestrienone, 445
  - use in patients with acute salpingitis, 107
- Ovarian function, effect of medroxyprogesterone acetate, 527
- Ovulation, effect of LHRH antagonistic analogues (rat, hamster, rabbit), 39
- Ovulation due to missing pill intake, ethinyl estradiol + norethisterone acetate, 241

## CONTRACEPTION

- Oxytocin augmentation,
  - complication and treatment rates during second-trimester abortion, 513
  - hypertonic saline instillation, 513
  - PGF<sub>2</sub> $\alpha$  instillation, 513
- Oxytocin, augmentation during second-trimester abortion, 513
- PG (prostaglandin)
- PGF<sub>2</sub> $\alpha$  analogue, luteolytic effect in non-pregnant women, 383
- PGF<sub>2</sub> $\alpha$  instillation, effect of oxytocin augmentation, 513
- Pharmacodynamics of ethinylestradiol,
  - ethinylestradiol + norethindrone, 85
  - ethinylestradiol + norgestrel, 85
  - mestranol + norethindrone, 85
  - single oral dose of ethinylestradiol, 85
- Pharmacokinetic study of different doses of medroxyprogesterone acetate, 527
- Pharmacokinetics,
  - ethinylestradiol, 457
  - norethindrone, 457
- Phenobarbital therapy,
  - interaction with ethinylestradiol + levonorgestrel, 495
  - interaction with ethinylestradiol + norethisterone acetate, 495
- 16-Phenoxy- $\omega$ -17,18,19,20-tetranor PGE<sub>2</sub> methyl sulfonylamide,
  - intramuscular injections for dilatation of cervix, 471
  - intramuscular injections for termination of early pregnancy, 471
- Phosphorus, serum levels during menstrual cycle, 63
- Plasmatic and vascular factors of hemostatic system, effect of mestranol + lynestrenol (rat), 249
- Plasminogen activator activity, mestranol + lynestrenol (rat), 249
- Post-abortion insertion, copper T 200, 561
- Postcoital contraception, estradiol-benzoate + estradiol-phenylpropionate, 165
- Post-coital IUD insertion, 653
- Post-partum T, post-placental insertion, 9
- Post-placental insertion of IUD, 9
- Post-sterilization complications, retrospective survey, 295
- Post-sterilization morbidity, retrospective survey, 295
- Potential impact of reversibility on selection of tubal sterilization, 227
- Preovulatory gonadotropin secretion inhibition, LHRH agonist (monkey), 313
- Progestagen-releasing IUD, association with ectopic pregnancy, 259
- Progesterone levels,
  - effect of LHRH agonist, 341
  - effect of LHRH agonist + HCG, 341

## CONTRACEPTION

- effect of d-norgestrel-releasing intracervical device (primate), 409
- effect of PGF<sub>2</sub> $\alpha$  analogue in non-pregnant women, 383
- use of (15S)-15-methyl-PGF<sub>2</sub> $\alpha$  methyl ester, 57, 137
- Progesterone-releasing IUD, endometrial estrogen and progesterin receptors, 19
- Progesterin receptors, effect of progesterone-releasing IUD, 19
- Prostacyclin activity, mestranol + lynestrenol, 249
- Prostaglandin (PG)
- Prostaglandin analogue,
  - 9-deoxo-16,16-dimethyl-9-methylene-PGE<sub>2</sub>, 153, 471
  - 16-phenoxo- $\omega$ -17,18,19,20-tetranor PGE<sub>2</sub> methyl sulfonylamide, 471
  - (15S)-15-methyl-PGF<sub>2</sub> $\alpha$  methyl ester, 57, 137
  - (15S)-15-methyl PGF<sub>2</sub> $\alpha$  (THAM), 623
- Prostaglandin E analogues, termination of early pregnancy and dilatation of cervix, 471
- Protein and nucleic acid composition of endometrial tissue, use of combined oral contraceptives, 425
- use of copper IUD, 425
- use of inert IUD, 425
- Quinesterol (3-cyclopentyl ether of ethinyloestradiol) effect on vaginal bleeding pattern during DMPA treatment, 1
- R2323 (13-ethyl-17 $\alpha$ -ethinyl-17 $\beta$ -hydroxygon-4,9,11-triene-3-one)
- R2323-releasing IUD, association with ectopic pregnancy, 259
- Rabbit vaginal contraception method, 659
- Radioimmunoassay of ethinylestradiol, presence of circulating norethindrone, 457
- Retrospective survey of sterilization, analysis of morbidity and post-sterilization complications, 295
- Reversible sterilization, potential impact on selection of tubal sterilization, 227
- (15S)-15-methyl-PGF<sub>2</sub> $\alpha$  free acid levels, use of (15S)-15-methyl-PGF<sub>2</sub> $\alpha$  methyl ester, 137
- (15S)-15-methyl-PGF<sub>2</sub> $\alpha$  methyl ester,
  - suppository for termination of early gestation, 137
  - suppository for termination of early pregnancy, 57
- 15(S)-15-methyl PGF<sub>2</sub> $\alpha$  peripheral levels, use of 15(S)-15-methyl PGF<sub>2</sub> $\alpha$  (methyl ester), 57
- (15S)-15-methyl PGF<sub>2</sub> $\alpha$  (THAM), intramuscular use for failure of mid-trimester abortion by another method, 623
- Salpingitis patients,
  - use of IUD, 107
  - use of oral contraceptives, 107
- Scanning electron microscopic study of luminal epithelium, endometrial effects of estradiol and levonorgestrel, 71
- Second-trimester abortion, oxytocin augmentation, 513
- Serum high density lipoprotein cholesterol levels, effect of DMPA, 359



## CONTRACEPTION

- Serum phosphorus levels during menstrual cycle, 63
- Sex hormone binding globulin capacity, interaction of phenobarbital and other anticonvulsants with oral contraceptive therapy, 495
- Sperm, inhibition of glycolysis by  $\alpha$ -chlorohydrin (boar), 505
- Sperm penetration test, effect of norgestrienone, 445
- Sperm recovery from fallopian tubes, effect of Lippes loop, 549
- Spermatozoa, effect of norgestrienone, 445
- Spermicidal effect of gossypol, 183
- Stereomorphometric study, ethinyl oestradiol and ethinyl-oestradiol + lynestrenol, 537
- Sterilization,  
    analysis of morbidity and post-sterilization complications, 295  
    potential impact of reversibility on acceptability, 227  
    reasons for objection, 213
- Steroid receptor levels, effect of progesterone-releasing IUD, 19
- Strength and relationship to failure of condoms during use, 31
- Subdermal implants, levonorgestrel, 71, 583
- TEPA (tris-1-aziridinylphosphine oxide), use in male fertility regulation (rat, hamster), 175
- Termination of early gestation, single vaginal suppository of (15S)-15-methyl-PGF<sub>2</sub> $\alpha$  methyl ester, 137
- Termination of early pregnancy,  
    single vaginal suppository of 15(S)-15-methyl PGF<sub>2</sub> $\alpha$  (methyl ester), 57  
    use of prostaglandin E analogues, 471
- Termination of mid-trimester pregnancy,  
    use of 9-deoxo-16,16-dimethyl-9-methylene-PGE<sub>2</sub>, 153  
    use of intramuscular (15S)-15-methyl PGF<sub>2</sub> $\alpha$  for failure of another method, 623
- Thio-TEPA (triethylene phosphoramidate), use in male fertility regulation (rat, hamster), 175
- Tissue distribution, nonoxynol-9 (rabbit), 325
- Transferrin saturation, effect of copper-bearing IUDs, 389
- Treatment rates and complication during second-trimester abortion, effect of oxytocin augmentation, 513
- Tubal sterilization,  
    objections, 213  
    potential impact of reversibility, 227
- Ultrastructural features of progestagen-induced decidual cells (monkey), 189
- Use-effectiveness, Nova-T and copper-T-200, 115
- Uterine contractility, effect of 9-deoxo-16,16-dimethyl-9-methylene-PGE<sub>2</sub>, 153
- Uterine effects of vasopressin analogue in first trimester pregnancy, 199
- Vaginal absorption, nonoxynol-9 (rabbit), 325


## CONTRACEPTION

- Vaginal bleeding pattern, effect of quinesterol during DMPA treatment, 1
- Vaginal contraceptive, effect of zinc salts (rabbit), 659
- Vaginal contraceptive tablets, clinical trial of Neo Sampooon, 573
- Valium, contraceptive effect (rabbit), 659
- Vascular and plasmatic factors of hemostatic system, effect of mestranol + lynestrenol (rat), 249
- Vasopressin analogue,  
8-lysine-vasopressin, 199  
myometrial effects in first trimester pregnancy, 199  
N- $\alpha$ -triglycyl-(8-lysine)-vasopressin, 199
- Weight, clinical effects of ethinyl estrogens with and without progestational agents, 369
- Weight gain, mechanism in DMPA users, 605
- White blood corpuscles in tubal washings, effect of Lippes loop, 549
- WHO, Task Force on IUD for Fertility Regulation, 9
- Zinc salts, effect in vaginal econtraceptives (rabbit), 659

Volume 22, 1980  
July-December, 1980  
ISSN 0010-7824

# **CONTRACEPTION**

**AN INTERNATIONAL JOURNAL**



**DANIEL R. MISHELL, Jr., M. D. — Editor**

***Publisher: GERON-X, INC., LOS ALTOS, CALIF.***

**EDITOR**

Daniel R. Mishell, Jr., M.D.  
Dept. of Obstetrics and Gynecology  
University of Southern California School of Medicine  
1240 North Mission Road  
Los Angeles, California 90033

**EDITORIAL ASSISTANT**

Elfi J. Martin

**BOARD OF ASSOCIATE EDITORS**

Wendy Baldwin, Ph.D.  
Behavioral Sciences Branch  
Center for Population Research  
National Institute of Child Health  
and Human Development  
Bethesda, Maryland 20014

Gerald S. Bernstein, Ph.D., M.D.  
Associate Professor  
Department of Obstetrics and  
Gynecology  
USC School of Medicine  
Los Angeles, California 90033

M.C. Chang, Ph.D., Sc.D.  
Senior Scientist  
Worcester Foundation for  
Experimental Biology  
Shrewsbury, Massachusetts 01545

Philip A. Corfman, M.D.  
Director of Population Research  
National Institute of Child Health  
and Human Development  
Bethesda, Maryland 20014

Jwe Goebelsmann, M.D.  
Director of the Reproductive  
Endocrinology Laboratory  
Nomen's Hospital  
1240 North Mission Road  
Los Angeles, California 90033

Joseph W. Goldzieher, M.D.  
Director, Division of Clinical  
Sciences  
Southwest Foundation for  
Research and Education  
San Antonio, Texas 78228

Roy O. Greep, Ph.D.  
Director  
Laboratory of Human Reproduc-  
tion & Reproductive Biology  
Harvard Medical School  
45 Shattuck Street  
Boston, Massachusetts 02115

Roy Hertz, M.D., Ph.D.  
Research Professor  
Departments of Pharmacology  
and Obstetrics and Gynecology  
George Washington University  
Medical Center  
Washington, D.C. 20037

William D. Odell, M.D., Ph.D.  
Professor and Chairman  
Department of Medicine  
Harbor General Hospital  
U.C.L.A. School of Medicine  
Torrance, California 90509

C. Alvin Paulsen, M.D.  
Professor of Medicine  
Department of Medicine  
University of Washington  
School of Medicine  
Seattle, Washington 98114

John J. Sciarra, M.D., Ph.D.  
Chief of Staff  
Prentice Women's Hospital and  
Maternity Center  
333 East Superior Street  
Chicago, Illinois 60611

Sheldon Segal, Ph.D.  
Director,  
Population Division  
Rockefeller Foundation  
1133 Avenue of the Americas  
New York, New York 10036

William N. Spellacy, M.D.  
Professor and Head  
Department of Obstetrics  
and Gynecology  
The Abraham Lincoln  
School of Medicine  
University of Illinois  
Medical Center  
840 South Wood Street  
Chicago, Illinois 60612

Howard J. Tatum, Ph.D., M.D.  
Associate Director  
Center for Biomedical Research  
Rockefeller University  
York Avenue & 66th Street  
New York, N.Y. 10021

# CONTRACEPTION

July 1980

Volume 22, Number 1

The Use of Quinesterol for the Control of Vaginal Bleeding Irregularities Caused by DMPA Parker, R.A. and McDaniel, E.B. ....	1
Comparative Multicentre Trial of Three IUDs Inserted Immediately Following Delivery of the Placenta WHO Task Force on Intrauterine Devices for Fertility Regulation .....	9
Endometrial Estrogen and Progestin Receptors in Women Bearing a Progesterone- Releasing Intrauterine Device Jänne, O. and Ylöstalo, P. ....	19
Immune Reactivity of Women on Hormonal Contraceptives. Phytohemagglutinin and Concanavalin-A Induced Lymphocyte Response Gerretsen, G., Kremer, J., Bleumink, E., Nater, J.P., de Gast, G.C. and The, T.H. ....	25
Relationship Between Condom Strength and Failure During Use Free, M.J., Skiens, E.W. and Morrow, M.M. ....	31
The Biological Effects of Two Antagonistic Analogues of Luteinizing Hormone Releasing Hormone Reel, J.R., Humphrey, R.R., Jones, D.C., Jordan, J.H., Pastushok, C.A., Sakowski, R., Windsor, B.L. and Edgren, R.A. ....	39
The Effect of a 15(S)-15-Methyl Prostaglandin F <sub>2α</sub> (Methyl Ester) Suppository Upon Termination of Early Pregnancy Roux, J.F., Southern, E. and Gutknecht, G. ....	57
Serum Phosphorus During the Menstrual Cycle Voda, A.M., Wilde, K. and Gill, B.P. ....	63
Endometrial Effects of Levonorgestrel and Estradiol: A Scanning Electron Microscopic Study of the Luminal Epithelium Nilsson, O., Englund, D., Weiner, E. and Victor, A. ....	71
Serum Levels of Ethinylestradiol Following Its Ingestion Alone or in Oral Contraceptive Formulations Brenner, P.F., Goebelsmann, U., Stanczyk, F.Z. and Mishell, D.R., Jr. ....	85
Letters to the Editor .....	97

# CONTRACEPTION

August 1980

Volume 22, Number 2

Intrauterine Contraceptive Device Use in Patients With Acute Salpingitis Paavonen, J. and Vesterinen, E.....	107
A Comparative Study of the Clinical Performance of Two Copper-Releasing IUDs, Nova-T and Copper-T-200 in Lagos, Nigeria Oyediran, M.A. and Akinla, O.....	115
Blood Coagulation and Idiopathic Thromboembolism Among Fertile Women Dreyer, N.A. and Pizzo, S.V.....	123
Termination of Early Gestation With a Single Vaginal Suppository of (15S)-15-Methyl-Prostaglandin F <sub>2</sub> α Methyl Ester Roy, S., Brenner, P.F., Marrs, R.P. and Mishell, D.R., Jr.....	137
Mid-Trimester Abortion by Vaginal Administration of 9-Deoxo-16, 16-Dimethyl-9-Methylene-PGE <sub>2</sub> Bygdeman, M., Christensen, N., Gr��en, K. and Lundstr��m, V.....	153
Postcoital Contraception With an Injectable Estrogen Preparation (ORG 369 - 2) Schindler, A.E., Ladanyi, S., G��ser, R. and Keller, E.....	165
Fertility Regulation in Male Rats and Hamsters With Alkylating Agents Hoyer, G.R. and Steward, R.....	175
<u>In Vitro</u> Spermicidal Activity of Gossypol Waller, D.P., Zaneveld, L.J.D. and Fong, H.H.S.....	183
The Ultrastructural Features of Progestagen-Induced Decidual Cells in the Rhesus Monkey ( <i>Macaca mulatta</i> ) Wadsworth, P.F., Lewis, D.J. and Heywood, R.....	189
Uterine Effects of N-��-Triglycyl-(8-Lysine)-Vasopressin and 8-Lysine- Vasopressin in the First Trimester of Pregnancy Laud��nski, T. and Akerlund, M.....	199
Announcement.....	209
Announcement.....	210
Announcement.....	211

# CONTRACEPTION

September 1980

Volume 22, Number 3

Objections to Tubal Sterilization: What Reversibility Can and Cannot Overcome Shain, R.N.....	213
The Potential Impact of Reversibility on Selection of Tubal Sterilization Shain, R.N.....	227
'Escape' Ovulation in Women Due to the Missing of Low Dose Combination Oral Contraceptive Pills Chowdhury, V., Joshi, U.M., Gopalkrishna, K., Betrabet, S., Mehta, S. and Saxena, B.N....	241
Plasmatic and Vascular Factors of the Hemostatic System in Rats Receiving an Estrogen- Progestogen Combination Roncaglioni, M.C., di Minno, G., Pangrazzi, J., Reyers, I., Mussoni, L., de Gaetano, G. and Donati, M.B.....	249
Ectopic Pregnancies Associated With Low Dose Progestagen-Releasing IUDs Diaz, S., Croxatto, H.B., Pavez, M., Quinteros, E., Carrillo, D., Simonetti, L., Croxatto, H-D. and Rosati, S.....	259
The Norgestrel-T IUD El-Mahgoub, S.....	271
Effects of a Luteinizing Hormone-Releasing Hormone Agonist on Luteal Function in Women Bergquist, C., Nillius, S.J. and Wide, L.....	287
A Retrospective Survey of Female Sterilization for the Years 1968 to 1973, Analysis of Morbidity and Post-Sterilization Complications for 5 Years Newton, J.R. and Gillman, S.....	295
Inhibition of Preovulatory Gonadotropin Secretion in the Rhesus Monkey by [ $\alpha$ -Glu-Pro] <sup>1</sup> , D-Phe <sup>2</sup> , D-Trp <sup>3,6</sup> ]-LHRH Wilks, J.W., Folkers K., Bowers, C.Y., Humphries, J., Schircks, B. and Friebl, K.....	313
Studies on Nonoxynol-9. II. Intravaginal Absorption, Distribution, Metabolism and Excretion in Rats and Rabbits Chvapil, M., Eskelson, C.D., Stiffel, V., Owen, J.A. and Droegemueller, W.....	325

# CONTRACEPTION

October 1980

Volume 22, Number 4

Luteolysis Induced by a Luteinizing Hormone-Releasing Hormone Agonist is Prevented by Human Chorionic Gonadotropin Bergquist, C., Nillius, S.J. and Wide, L.....	341
17 $\beta$ -Estradiol Levels in Blood and Cerebrospinal Fluid After Ocular and Nasal Administration in Women and Female Rhesus Monkeys ( <i>Macaca mulatta</i> ) Öhman, L., Hahnenberger, R. and Johansson, E.D.B.....	349
Serum High Density Lipoprotein Cholesterol Levels in Women Using a Contraceptive Injection of Depot-Medroxyprogesterone Acetate Kremer, J., de Bruijn, H.W.A. and Hindriks, F.R.....	359
Clinical Effects of Ethynyl Estrogens, Used With and Without Progestational Agents, on Bleeding Patterns, Weight and Blood Pressure Goldzieher, J.W., Chenault, C.B., Woutersz, T.B., Schneider, B.E. and Hansen, P.R.....	369
A Luteolytic Effect of a Prostaglandin F $_{2\alpha}$ Analogue in Non Pregnant Women ? Hamberger, L., Källfelt, B., Forshell, S. and Dukes, M. ....	383
A Longitudinal Study of Serum Iron Indices and Haemoglobin Concentration Following Copper-IUD Insertion Goh, T.H., Hariharan, M. and Tan, C.H.....	389
A Clinical and Metabolic Study of Norethisterone Oenanthate in Thai Women Virutamasen, P., Nitichai, Y., Tangkeow, P., Kankeerati, W., Rienprayura, D. and Boonsiri, B.....	397
Effects of d-Norgestrel-Releasing Intracervical Devices in the Nonhuman Primate, <i>Erythrocebus patas</i> Dagle, G.E., Sikov, M.R., Rowe, S.E., Burton, F.G. and Skiens, W.E.....	409
Effects of Contraceptive Agents on the Biochemical and Protein Composition of Human Endometrium Umapathysivam, K. and Jones, W.R.....	425
The Incidence of Gonorrhea in an Abortion Population Querido, L. and Haspels, A.A.....	441



# CONTRACEPTION

November 1980

Volume 22, Number 5

Experimental Study of Cervical Blockage Induced by Continuous Low-Dose Oral Progestogens Chretien, F.C., Sureau, C. and Neau, C.....	445
Radioimmunoassay of Plasma Ethinylestradiol in the Presence of Circulating Norethindrone Stanczyk, F.Z., Gale, J.A., Goebelsmann, U., Nerenberg, C. and Matin, S.....	457
A Comparison of Two Stable Prostaglandin E Analogues for Termination of Early Pregnancy and for Cervical Dilatation Bygdeman, M., Bremme, K., Christensen, N., Lundström, V. and Gréen, K.....	471
Transfer of Cyproterone Acetate to the Milk of Lactating Women Stoppelli, I., Rainer, E. and Hümpel, M.....	485
The Interaction of Phenobarbital and Other Anticonvulsants With Oral Contraceptive Steroid Therapy Back, D.J., Bates, M., Bowden, A., Breckenridge, A.M., Hall, M.J., Jones, H., MacIver, M., Orme, M., Perucca, E., Richens, A., Rowe, P.H. and Smith, E.....	495
Inhibition of Glycolysis in Boar Sperm by $\alpha$ -Chlorohydrin Hutton, P., Dawson, A.G. and Jones, A.R.....	505
Oxytocin Augmentation of Second-Trimester Abortion: Safe or Hazardous? Cates, W., Jr. and Schulz, K.F.....	513
Pharmacokinetic Study of Different Doses of Depo Provera Fotherby, K., Koetsawang, S. and Mathrubutham, M.....	527
Combined Clinical, Histological and Stereomorphometric Studies with a New Oral Contraceptive of Normophasic Type: Fysioquens Dombrowicz, N. and Van de Walle, J.....	537
Effect of Lippes Loop on Sperm Recovery From Human Fallopian Tubes El-Habashi, M., El-Sahwi, S., Gawish, S. and Osman, M.....	549
Erratum.....	557
Announcement.....	559

# CONTRACEPTION

December 1980

Volume 22, Number 6

Five Years Experience With the Copper T 200 in Shanghai - 856 Cases Pei-zhu, Z.....	561
A Clinical Trial of Neo Sampooon Vaginal Contraceptive Tablets Begum, S.F., Liao, W.C., McCann, M.F. and Ahmed, N.....	573
Plasma Levels of Levonorgestrel in Women During Longterm Use of Norplants Croatto, H.B., Diaz, S., Miranda, P., Elamsson, K. and Johansson, E.D.B.....	583
Liver Function Tests and Low-Dose Estrogen Oral Contraceptives Dickerson, J., Bressler, R. and Christian, C.D.....	597
A Study of the Mechanism of Weight Gain in Medroxyprogesterone Acetate Users Amatayakul, K., Sivasomboon, B. and Thanangkul, O.....	605
Use of Intramuscular Prostaglandin for Failure of Mid-Trimester Abortion by Another Method Schwallie, P.C., Huang, D.C. and Turner, L.F.....	623
A Study of Interaction of Low-Dose Combination Oral Contraceptive With Ampicillin and Metronidazole Joshi, J.V., Joshi, U.M., Sankholi, G.M., Krishna, U., Mandekar, A., Chowdhury, V., Hazari, K., Gupta, K., Sheth, U.K. and Saxena, B.N.....	643
Post-Coital Intrauterine Device Insertion - A Further Evaluation Black, T.R.L., Goldstuck, N.D. and Spence, A.....	653
New Antifertility Agents Active in the Rabbit Vaginal Contraception (RVC) Method Williams, W.L.....	659
Fertility and Electrolyte Composition of the Rat Cauda Epididymal Plasma and Spermatozoa Before and After Castration Pholpramool, C. and Sornpaisarn, L.....	673
Announcement.....	683
Announcement.....	684
Author Index for Volume 22.....	685
Subject Index for Volume 22.....	689

